Title: The Child with Tics or Other Common Movement Disorders

Keisuke Ueda, MD1, Kevin J. Black, MD1, 2, 3, 4

1. Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA

2. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA

3. Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA

4. Department of Neuroscience, Washington University School of Medicine, St. Louis, MO, USA

Keisuke Ueda
660 S Euclid Avenue
Campus Box 8111
St. Louis, MO 63110-1093
Phone: 314-454-6120
Email: k.ueda@wustl.edu

Kevin J. Black
660 S Euclid Avenue
Campus Box 8134
St. Louis, MO 63110-1093
Phone: 314-362-4621
Email: kevin@wustl.edu

Tables: 0

Figures: 0

Acknowledgments

A draft of this article was archived on the Open Science Framework (<https://osf.io/ehz7u>).

Abstract Tic disorders are the most common movement disorders in a pediatric practice. Moreover, tic disorders are frequently associated with comorbid neuropsychiatric symptoms. Therefore, understanding tic disorders is vital for general practitioners to deliver appropriate care to patients with tics. However, misunderstanding and misconceptions of tic disorders still exist among the general population and in health care providers. For the past decade, many studies have been conducted to elucidate tic disorders. This article aims to provide an overview about tics and tic disorders, and recent information on tic disorders including history, definition, diagnosis, epidemiology, etiology, diagnostic approach, comorbidities, treatment and management, and differential diagnosis.

Key words (5-10): tics, Tourette syndrome, natural course, treatment, differential diagnosis, pediatric movement disorder, premonitory urge, comorbid symptoms

1 Introduction/Definition

Movement disorders are central nervous system disorders that cause abnormal, unwanted movements and are usually unrelated to weakness, or spasticity. Dysfunction of the basal ganglia and frontal cortex plays an important role in most movement disorders in children (Mink 2003). Conventionally, movement disorders are divided into two categories. The first category is hyperkinetic movement disorders, associated with an excess of movement (e.g., excessive, unnatural, and involuntary movement). These include tics, stereotypies, chorea, myoclonus, dystonia, and tremor (Fahn et al. 2011). The second group is hypokinetic movement disorders, with a paucity of movement (e.g., decreased amplitude, decreased speed, or loss of movement), including bradykinesia, akinesia, and rigidity (Fahn et al. 2011). Unlike hypokinetic movement disorders, hyperkinetic movement disorders, especially tic disorders, are relatively common in the pediatric population.

The most common movement disorders in the pediatric population are tic disorders, including Tourette syndrome (TS). In 1825, Jean-Marc Gaspard Itard reported the case of a French noblewoman who exhibited involuntary body movements involving the shoulders, neck, and face, and vocalization such as making barking sounds and uttering obscene language (Lavoie and O'Connor 2017). Subsequently, George Gilles de la Tourette referred to this case and reported nine patients with tic disorders (Fahn et al. 2011). Notably, these reports described the essential clinical features of tic disorders, such as early onset, waxing and waning course, echolalia, coprolalia, and echopraxia. For some time, a tic was regarded as a symptom of functional disorders including hysteria, neurosis, or narcissism. In 1968, the first case was reported of a patient whose tics improved with neuroleptics (Shapiro and Shapiro 1968). Since then, tic disorders have been discussed primarily in a neurobiological context. They are frequently accompanied by psychiatric comorbidities such as attention-deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), anxiety, and depression. Optimal treatment of tic disorders therefore requires a multidisciplinary approach involving neurologists, psychiatrists, psychologists, and behavioral therapists.

Tics are defined as “sudden, rapid, recurrent, nonrhythmic motor movement (motor tics) or vocalization (vocal or phonic tics)” (American Psychiatric Association 2013). Both motor and vocal tics are classified as simple or complex, although differentiating a simple tic from a complex tic is not always straightforward. Simple motor tics are brief, abrupt, repetitive, and seemingly non-purposeful movements and involve only one muscle group or body part (e.g., face, neck, shoulders, or hands) (Singer et al. 2016). Motor tics most frequently involve the eyes and mouth, followed by the neck and limbs; feet and midline axial struc-

tures are the least frequently involved (Ganos et al. 2015; Pappert et al. 2003). Examples of motor tics include blinking, eye rolling, wide opening of the eyes or mouth, tilting the neck, raising the shoulders, and hand-moving. Based on their phenomenology, simple motor tics are subdivided into three groups: clonic, dystonic, and tonic tics (Jankovic 2001). Clonic tics are abrupt, rapid, brief jerking movements (e.g., blinking, facial grimacing, head jerking). Dystonic tics are slower, resulting in briefly, sustained abnormal postures (e.g., a prolonged involuntary upward deviation of the eyes, eye closure, bruxism, mouth opening, or torticollis). Tonic tics are isometric contractions (e.g., tensing of abdominal and limb muscles) (Jankovic 2001; Jankovic 1997). Some tics may result in transient interruption of ongoing motor activities or speech without loss of consciousness. Such tics are often referred to as blocking tics (Jankovic and Kurlan 2011). By contrast, complex motor tics are caused by several muscle groups and sometimes appear to be purposeful, coordinated, or orchestrated patterns of movement. Examples include touching, tapping, waving, kicking, jumping, echopraxia (mimicking others' gestures), and copropraxia (performing obscene or forbidden gestures or inappropriate touching).

Simple vocal tics are meaningless sounds made by moving air through the nose, mouth, or throat. Vocal tics are often referred to as "phonic tics," because the sound may be produced not only by contraction of the vocal cords but also by contraction of the nasal, oral, laryngeal, pharyngeal, and respiratory muscles. Examples include coughing, throat clearing, grunting, mimicking animal noises, and tongue clicking. Complex vocal tics involve several muscle groups and are characterized by words, phrases, or sentences. Examples include shouting and yelling, echolalia (repeating another person's words), and coprolalia (uttering socially inappropriate expressions). Coprolalia is seen in 8%–17% of patients with TS, and its onset is usually around the age of 15 years (Goldenberg et al. 1994; Kurlan et al. 1986; Robertson 2000).

The Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), defines five tic disorders: Provisional Tic Disorder, Persistent (chronic) Motor or Vocal Tic Disorder, Tourette's Disorder (also known as Tourette syndrome), Other Specified Tic Disorder, and Unspecified Tic Disorder (American Psychiatric Association 2013). The first three tic disorders require the onset be before age 18 years and the symptoms not be caused by other medical illnesses such as Huntington's disease, substance abuse, or medication side effects. Provisional Tic Disorder is considered when tics (motor or vocal or both) have been present for less than one year since tic onset. Both TS and Persistent (chronic) Motor or Vocal Tic Disorder indicate the presence of tics for longer than one year (though intervening tic-free periods are allowed). Persistent (chronic) Motor or Vocal Tic Disorder is diagnosed when individuals have exhibited either motor or vocal tics (but not both) at some time during the illness. When both motor and vocal tics occur during the course of the disease, though not necessarily concurrently, TS is diagnosed. Patients with TS tend to have a higher severity of tics, greater prevalence of complex motor tics (e.g., copropraxia and echopraxia), and more comorbid symp-

toms than patients with Persistent Motor Tic Disorder (Müller-Vahl et al. 2019). The final two DSM-5 tic disorders are used for patients whose presentation does not fit the first three. Importantly, the diagnostic criteria of tic disorders do not mention tic severity.

Under the DSM-IV, a diagnosis of Transient Tic Disorder required tics lasting for at least four weeks, and Persistent Tic Disorder and TS required a year of tics *without* a tic-free period of more than three consecutive months. These criteria were removed from the DSM-5. There was no factual basis for the four-week limit and most tic symptoms last longer than four weeks. The criterion of “three consecutive months” was not supported by epidemiological studies (Roessner et al. 2011a). Furthermore, “Transient” Tic Disorder was changed to “Provisional” Tic Disorder in the DSM-5 due to confusion about the meaning of “transient” (Black et al. 2016). Although some motor tics are stereotyped, the word “stereotyped” has not been used in the definitions of tics to avoid confusion between tics and Stereotypic Movement Disorder. In the DSM-IV, tic disorders had to cause clinically significant impairment or distress to patients, but this criterion was removed beginning with DSM-IV-TR. Tic symptoms do not always cause such an impairment. Indeed, many children with tics are not always bothered by their tics, but rather by other neuropsychiatric comorbidities (Eapen et al. 2016).

2 Epidemiology

It is difficult to estimate the true prevalence of tic disorders, because a significant number of people do not recognize their tics or do not seek medical care (Cubo 2012; Kurlan et al. 1987). The reported prevalence of tics in children therefore varies considerably (Knight et al. 2012; Robertson 2008a, 2008b). Tics are more likely to affect boys than girls by a ratio of 1.5–4:1 (Knight et al. 2012; Snider et al. 2002; Stefanoff et al. 2008). The incidence of motor tics is higher in the winter months than in the spring months (Snider et al. 2002). In a direct observational study where the researchers went to local schools to rate children’s tics, at least one motor tic was noted in 47% of 1st-grade students and 15% of 6th-grade students, and the overall cross-sectional prevalence of tics during childhood was approximately 19%–24% (Black et al. 2016; Kurlan et al. 2001; Snider et al. 2002). Other observational studies using questionnaires revealed that tics were found in 22% of preschool children, 7.8% of elementary school children, and 3.4% of adolescents (Gadow et al. 2002). A similar tendency has been observed in other countries. For example, in Poland, the overall lifetime prevalence of tics is 9.9% (12% for boys and 7.7% for girls) (Stefanoff et al. 2008). In Spain, tics were noted in about 17% of school-aged students (19% for boys and 13% for girls) (Cubo et al. 2011). The prevalence of tics in children receiving special education was estimated to be 20%–23%, with 5.3%–7.0% of them meeting the criteria for TS (Cubo et al. 2011; Kurlan et al. 2001).

The prevalence of TS is estimated at around 0.4%–3% in regular school students (Alves and Quagliato 2014; Hornsey et al. 2001; Khalifa and Knorrning 2003; Mason et al. 1998). Furthermore, the prevalence of TS in children with autistic spectrum disorder is higher: 22% of children with autistic spectrum disorder were found to have chronic motor tics and 11% were diagnosed with TS (Canitano and Vivanti 2007).

Tic disorders are the most common movement disorders in the pediatric population, but adult-onset primary tic disorder is rare (Black et al. 2020; Robakis 2017) and is usually associated with underlying neuropsychiatric disorders (e.g., Down syndrome, Huntington's disease, neuroacanthocytosis) (Jankovic and Ashizawa 1995; Mejia and Jankovic 2005), head or peripheral trauma (Factor and Molho 1997; Singer et al. 1989), basal ganglia stroke (Bansil et al. 2012), HIV infection (Aquino et al. 2010), and neuroleptic side effects or cocaine abuse (Bharucha and Sethi 1995; Kumar and Lang 1997; Pascual-Leone and Dhuna 1990). Indeed, many adult tics are reoccurrences or continuations of childhood tics (Goetz et al. 1992; Klawans and Barr 1985).

3 Etiology

The pathophysiology of tic disorders involves impaired function of corticostriatal-thalamic-cortical circuits with aberrant associated neurotransmitter function, including dopamine, serotonin, and gamma-aminobutyric acid (GABA), and development-related atypical functional brain connectivity (Albin and Mink 2006; Augustine and Singer 2019; Church et al. 2009; Leckman 2002; Nielsen et al. 2020; Peterson et al. 2003; Singer 2005; Yael et al. 2015). The etiology of tic disorders is complicated and multifactorial, including polygenic factors and non-genetic factors such as environmental factors and immune-mediated mechanisms, contributing to the heterogeneous clinical phenotype (Robertson et al. 2017).

3.1 Environmental factors

The environmental influence on the phenotype of tic disorders has remained elusive. Various studies have investigated prenatal and perinatal epigenetic factors. In a direct interview study, the severity of tics correlated positively with various factors. A direct interview study found a correlation of tics with maternal life stress during pregnancy and nausea and vomiting during the first trimester of pregnancy (Leckman et al. 1990); a retrospective review study found a correlation with early prenatal care in the first trimester, more prenatal visits, decrease in the APGAR score at five minutes, and the month when prenatal care began (Burd et al. 1999); and a systematic review found a correlation with low birth weight and prenatal maternal smoking (Chao et al. 2014). However, a prospective, population-based, pre-birth cohort study identified alcohol use during pregnancy, cannabis use during pregnancy, and parity and inadequate weight gain during pregnancy

as prenatal risk factors for chronic tic disorder, but other risk factors such as prenatal maternal smoking, gestational age, low birth weight, and complications of delivery were not associated with tic disorders (Mathews et al. 2014).

In a case-control study (Leivonen et al. 2017), parental psychiatric disorders (especially in mothers) were associated with a greater likelihood of children developing TS and chronic tic disorders. A questionnaire survey showed that children from nuclear families with poor parental relationships were at more risk of developing TS (Zhu et al. 2020). However, the onset of tics was not associated with stressful life events (Horesh et al. 2008).

3.2 Genetic etiology

In 1885, Georges Gilles de la Tourette pointed out possible genetic factors of tic disorders (Pauls et al. 2014). Since then, numerous studies have investigated genetic factors in tic disorders (Pauls et al. 2014). Segregation analyses of 27 families with TS patients demonstrated autosomal dominant transmission patterns (Pauls and Leckman 1986). A twin study with probable monozygotic (MZ) and dizygotic (DZ) twins showed that concordance rates for tics were 77% and 23% for MZ and DZ pairs respectively, and those for TS were 53% and 8% for MZ and DZ pairs respectively (Price et al. 1985). A subsequent study with MZ twins also showed high concordance rates of 94% for tic disorders and 56% for TS, which indicates genetic etiology with high penetrance (Hyde et al. 1992).

Currently, tic disorders and TS are considered to be polygenic inherited disorders involving a large number of different genes. In a population-based cohort study using the Genome-wide Complex Trait Analysis program, the heritability estimate of TS was given as 0.58–0.77 (Davis et al. 2013; Mataix-Cols et al. 2015). The same population-based study also revealed that the risk of developing tic disorders for first-degree relatives of probands with tic disorders was significantly higher than that for second and third-degree relatives (Mataix-Cols et al. 2015). Full siblings of individuals with tic disorders have a significantly higher risk of developing tic disorders than maternal half-siblings, regardless of similar environmental exposure, suggesting that the environment is not important in causing tic disorders (Mataix-Cols et al. 2015).

Several candidate susceptibility genes for TS have been suggested but have not been confirmed yet, probably because of the small sample size of each study and genetic and phenotypic heterogeneity (Georgitsi et al. 2016). A family with TS had an insertion or translocation of chromosomes 2 and 7 disrupting the *CNTNAP2* gene on chromosome 7q35-q36, probably leading to disturbed distribution in potassium channels in the nervous system (Verkerk et al. 2003). Another case report of a family with TS showed that a deletion of exons 4, 5, and 6 of the *NLGN4* gene on chromosome Xp22.32-p22.31 was associated with TS and neuropsychiatric disorders such as autistic spectrum disorder, ADHD, learning disorders, anxiety, and depression (Lawson-Yuen et al. 2008). The *SLITRK1* gene on chromosome 13q31.1, which encodes a single-pass transmembrane protein in the

central nervous system, may be associated with TS as well as obsessive-compulsive disorders and schizophrenia (Abelson et al. 2005; Proenca et al. 2011). The *HDC* gene on chromosome 15q21.2 encodes L-histidine decarboxylase that plays a role in histidine metabolism. A mutation in the *HDC* gene may be implicated in tics and TS by affecting histaminergic neurotransmission (Ercan-Sencicek et al. 2010). The *IMMP2L* gene on chromosome 7q31.1 encoding the inner mitochondrial membrane peptidase subunit 2 has also been implicated in TS (Patel et al. 2011; Petek et al. 2001). In an animal study, the *Imp2l* mutation caused excessive mitochondrial superoxide generation and an increase in cellular oxidative stress (George et al. 2011). However, a recent study using skin fibroblasts from patients with TS with the *IMMP2L* deletions revealed no evidence of substantial mitochondrial dysfunction in GTS fibroblasts (Bjerregaard et al. 2020).

A genome-wide screening of single nucleotide polymorphism (SNP) genotyping microarray with patients with TS showed 5 exon-affecting rare copy number variants involving the *NRXN1*, *AADAC*, *CTNNA3*, *FSCB*, *KCHE1-KCHE2-RCAN1* genes (Sundaram et al. 2010). An analysis of a European ancestry sample of TS cases for rare (< 1% frequency) copy number variants using SNP microarray data demonstrated that the *NRXN1* deletions and *CNTN6* duplications were associated with a substantially increased risk of developing TS (Huang et al. 2017). Whole-exome sequencing studies identified the *CELSR3* gene on chromosome 3p21.31 (Wang et al. 2018) and the *ASH1L* gene on chromosome 1q22 (Liu et al. 2020) as high-risk genes for TS. Exome sequencing in patients with TS revealed possibly disrupting variants of the *OPRK1* gene on chromosome 8q11.23, encoding the opioid kappa receptor (Depienne et al. 2019). The Brainstorm Consortium genome-wide association studies (GWAS) of TS have indicated an association between TS and the *COL27A1* gene on chromosome 9q32-33 (Liu et al. 2015; Scharf et al. 2013). Their results converge to the conclusion that tic disorders are not single-gene disorders, but genetic predisposition with environmental factors might increase the risk of developing tic disorders. Further studies are necessary to establish biological correlates of these genes and tic disorders.

3.3 Immunologic mechanism

Abnormal immune responses have been proposed as underlying causes of tics, and such proposals have prompted investigation with different approaches, including animal studies, post-mortem studies, and laboratory studies. These studies have revealed some evidence for immune-mediated mechanisms, including impaired activation of the innate immune response, especially to bacterial infection (Weidinger et al. 2014); elevation of interleukin-12 and tumor necrosis factor at baseline (Leckman et al. 2005); deficit in T-cell regulation (Kawikova et al. 2007); increased titers of adhesion molecules as markers of a systemic inflammatory response (Martino et al. 2005); altered immunoglobulin profile (Bos-Veneman et al. 2011); presence of oligoclonal bands in central spinal fluid (Wenzel et al. 2011);

microglial involvement; over-activity of systemic immune responses; and dysfunctional neural-immune crosstalk (Martino et al. 2015).

Some cases of TS may represent a central nervous system autoimmune disorder following infection. In 1978, a case was reported of an 11-year-old boy who developed severe tic symptoms after a febrile streptococcal infection, evidenced by elevated anti-streptolysin O (ASO) titers (Kondo and Kabasawa 1978). The patient did not respond to haloperidol but responded dramatically to prednisolone. In 1992, it was reported that two children developed tic symptoms after a streptococcal infection and also did not respond to neuroleptics but reached complete remission with adrenocorticotrophic hormone and prednisone (Matarazzo 1992). A clinical study of children with recent onset of movement disorders (tics and chorea) found that children with these movement disorders were more likely than those without to be positive for an anti-neuronal antibody directed against caudate nuclei and had elevated ASO titers than children without the movement disorders (Kiessling et al. 1993). Subsequent case-control studies of patients with TS showed a significant increase in streptococcal antibodies such as ASO and anti-basal ganglia antibodies (Rizzo et al. 2006), and antibodies against putamen, but not the caudate or globus pallidus (Singer et al. 1998). A large case-control study of 150 children with tic disorders demonstrated a significant elevation of ASO titers in children with tics compared to those of controls and a positive correlation between ASO titers and tic severity (Cardona and Orefici 2001). A cross-sectional study comparing children and adults with TS to children with other neurological diseases, children with recent uncomplicated streptococcal infections, adults with neurological disease, and healthy adults, revealed a significant elevation of ASO titers in both children and adults with TS (Church et al. 2003). The most common basal ganglia binding antigen was similar to the proposed antigen in Sydenham's chorea (Church et al. 2003). Thus, an autoimmune process caused by the cross-reacting of streptococcal bacterial antigens to the brain anti-neuronal antibodies, similar to the process of Sydenham's chorea, was suggested as a pathophysiological mechanism of TS.

Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) has been hypothesized as a subset of children with acute onset of tics or OCD following streptococcal infection. The diagnostic criteria include the following: (1) the presence of either OCD or tic disorder or both; (2) onset before puberty (usually between 3 and 12 years of age); (3) abrupt, dramatic, and explosive onset; (4) a relapsing and remitting clinical course of symptoms with temporal relation associated with streptococcus infection; and (5) other neurological symptoms such as hyperactivity, anxiety, choreiform movements, or tics during exacerbations (Swedo et al. 2004). The pathophysiology of PANDAS is hypothesized to be related to IgG anti-neuronal autoantibodies produced through the process of molecular mimicry between host and group A streptococcus (GAS), which penetrate the blood-brain barrier and potentially induce neuronal signal transduction and subsequent excess dopamine release (Cunningham 2019).

The findings of many studies, however, are inconsistent with the hypothesis of streptococcal infection inducing autoimmune-mediated antibodies to the basal ganglia and causing tic symptoms. In a case-control study of patients with TS, Sydenham chorea, autoimmune disorders, and healthy controls, IgG class anti-neural and anti-nuclear antibody titers were no longer significant when patients were stratified by age (Morshed et al. 2001). The same study also showed no significant difference in clinical symptoms depending on the autoantibody positivity. Other methodologies such as enzyme-linked immunosorbent assay (ELISA) and Western immunoblotting demonstrated no total autoantibody abnormality to the caudate, putamen, and prefrontal cortex in patients with TS and PANDAS (Singer et al. 2005).

Multiple concerns about the diagnosis and treatment of PANDAS have been raised (Gilbert 2019; Singer 2017). It is not straightforward to distinguish PANDAS from TS clinically, as they have several similarities. The onset of PANDAS overlaps that of TS. Both PANDAS and TS have a relapsing and remitting clinical course. Symptoms of TS are typically worsened by physical and emotional stress, anxiety, or infection. A study using clinical interviews showed that acute onset or exacerbation of tics was frequently seen in children with tic disorders (53%), which suggests that an explosive onset of tic symptoms is not unique to PANDAS (Singer et al. 2000). Indeed, many children with PANDAS have pre-existing tics before the diagnosis of PANDAS, and so the abrupt, dramatic, and explosive onset of tics with the GAS infection might be the natural course of tic disorders. Patients with a diagnosis of presumed PANDAS might have a predisposition to tic disorders before the onset of PANDAS. An observational study showed that first-degree relatives of children with PANDAS had a higher rate of OCD and TS than was reported in the general population (Lougee et al. 2000).

Another concern for PANDAS is that no accurate diagnostic test exists to confirm or rule out PANDAS (Gilbert et al. 2018a). Diagnoses of PANDAS are often made based on incomplete criteria, and most patients referred to specialty clinics with a pre-diagnosis of PANDAS do not fulfill the diagnostic criteria of PANDAS (Gabbay et al. 2008; Helm and Blackwood 2015). Making a diagnosis of a streptococcal infection is not always straightforward (Singer et al. 2012). The sensitivity of a rapid streptococcal antigen detection test was low in children without clinical GAS symptoms such as tonsillar exudate or swelling, tender cervical lymphadenopathy, fever, and absence of a cough (Edmonson and Farwell 2005). Even positive throat culture may represent a GAS carrier state that does not require antibiotic treatment (Gerber et al. 1988). The anti-streptococcal antibody titers such as ASO and antideoxyribonuclease B need to be interpreted carefully. A prospective study revealed that 16% of children remained positive for the homologous serotype for more than 12 months after the infection, suggesting that single elevated antibody titers are often misleading and may only indicate antibody persistence from an infection that occurred one year earlier (Johnson et al. 2010). Single time-point cultures and single antibody titers are not sufficient to define the infection; sequential sampling of two different antibodies is necessary to make an

accurate diagnosis of GAS infection (Johnson et al. 2010). As group C and G streptococci also produce antigenically identical ASO, the elevation of the ASO is not always linked to GAS infection (Johnson et al. 2010; Singer et al. 2012).

Commercial antibody panel testing, such as the Cunningham Panel, is available for the diagnosis of PANDAS. This testing measures the human serum IgG level by ELISA directed against the dopamine D1 receptor, dopamine D2L receptor, lysoganglioside-GM1, and tubulin, and measures the activity of calcium/calmodulin-dependent protein kinase II (Shimasaki et al. 2020). However, the reliability of the Cunningham Panel is unclear. A case-control study to assess the diagnostic accuracy of the Cunningham Panel in patients with PANDAS or pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANS) showed low sensitivities (15%–60%), variable specificities (28%–92%), and low positive predictive values (17%–40%) and negative predictive values (44%–74%) (Hesselmark and Bejerot 2017). The same study also showed elevated CaMKII activity in 48% (10/21) of healthy controls and 66% (35/53) of patients with PANDAS or PANS. Moreover, at least one autoantibody titer was positive in 86% of the healthy controls compared to 92% of the patients. The European Multicentre Tics in Children Studies (EMTICS) study, a large longitudinal observational European multicenter project, investigated the role of environmental factors (e.g., GAS exposure) in the tic disorders (Schrag et al. 2019). The data from the EMTICS study failed to show evidence of specific neuronal surface antibodies in children with TS (Baglioni et al. 2019). A prospective cerebrospinal fluid (CSF) analysis study with adults with TS also failed to demonstrate specific autoantibodies in the CSF (Baumgaertel et al. 2019).

The treatment of PANDAS is also extremely controversial. The first-line treatment for acute and chronic PANDAS is a symptomatic approach with psychological and pharmacological interventions (Thienemann et al. 2017). In light of the possible autoimmune mechanism, anti-inflammatory and immunomodulatory therapies (e.g., corticosteroids, NSAIDs, intravenous immunoglobulins [IVIG], therapeutic plasma exchange, rituximab) have been used for the acute phase (Frankovich et al. 2017). In double-blind placebo-control studies (Hoekstra et al. 2004; Williams et al. 2016), however, IVIG did not significantly reduce tic severity or OCD symptoms. In contrast, a single placebo-controlled study using IVIG and plasmapheresis for patients with severe, infection-triggered exacerbations of OCD or tic disorders, including TS, showed that plasmapheresis showed reduction of tic severity, as measured by the Tourette Syndrome Unified Rating Scale, but IVIG did not (Perlmutter et al. 1999).

4 Diagnostic Approach

4.1 History

In clinical practice, the diagnosis of tics is usually straightforward and can be made by reference to the patient's clinical history. It does not require any laboratory testing or neurological imaging studies. Understanding the natural course of tics is therefore essential. Tics usually begin between 3 and 8 years of age. Conventionally, most tics are believed to go away on their own within a few months. A prospective cohort study of 43 children with early onset of tics, however, found that all the children still experienced tics one year after onset, although the experience was minimal or milder (Kim et al. 2019). One explanation for this discrepancy is related to the benign nature of tic disorders. If tics are minimal or mild and do not cause any impairment or distress, patients and family members may not recognize them or feel it necessary to seek medical attention. If patients do not return to the clinic, this may be misinterpreted as remission of the tics. If tics persist for more than one year, the severity usually peaks around 8–12 years of age. Most patients with tics experience significant improvement or complete resolution by early adulthood (Leckman et al. 1998). The first tic symptoms are usually simple motor tics involving the face, head, or neck. Tics then spread in the rostro-caudal direction over time (Bloch and Leckman 2009a). The first vocal tics occur on average a few years after the onset of motor tics and are usually simple vocal tics such as throat clearing or sniffing (Bloch and Leckman 2009a).

Several characteristics are useful in identifying tics. Tics usually follow a waxing and waning pattern in severity and frequency, with a mixture of old and new tics. Although the onset of TS does not seem to be associated with life events, the exacerbations and fluctuating nature of tics are related to environmental factors (Horesh et al. 2008). Tics may be temporarily exacerbated by psychological strains (e.g., stress, anxiety, excitement, anger), physical strains (e.g., fatigue, sleep deprivation, and infections), and environmental changes. This exacerbation is usually transient and subsides after the cause resolves. Individuals with tics often experience an unpleasant sensation preceding the tics, referred to as a premonitory urge, which is temporarily relieved by the execution of the tics (Bliss et al. 1980; Leckman 2002; Woods et al. 2005). Over 90% of adolescents and adults with TS (Kwak et al. 2003a; Leckman et al. 1993; Reese et al. 2014) and 37% of children with TS from age 8 to 19 years (Banaschewski et al. 2003) reportedly experience premonitory urges to some extent. Unlike other movement disorders, tics may be voluntarily suppressed for variable periods, which is known as tic suppressibility (Jankovic 1997; Koller and Biary 1989; Ueda et al. 2020).

Tourette syndrome is frequently comorbid with other psychiatric symptoms, such as ADHD, OCD, autistic spectrum disorder, depression, anxiety disorder, sleep disorders, and migraine (Eddy et al. 2011b; Ghosh et al. 2014; Kwak et al. 2003b; Marwitz and Pringsheim 2018; Piedad and Cavanna 2016; Robertson 2015). About 85%–88% of patients with TS have at least one psychiatric comorbidity that usually appears between the ages of 4 and 10 years (Freeman et al. 2000; Hirschtritt et al. 2015). The most common comorbidities are ADHD and OCD. Other disorders (e.g., mood disorder, anxiety, disruptive behavior) have

been found to occur in about 30% of patients with TS (Hirschtritt et al. 2015). In the Brainstorm Consortium GWAS of 265,218 patients and 784,643 controls, TS shared common variant genetic risk with ADHD, major depressive disorder, OCD and migraine (with aura) (Brainstorm Consortium 2018). Similarly, ADHD and OCD symptom clusters were genetically related to a diagnosis of TS (Hirschtritt et al. 2018).

Even when tic symptoms do not impair social, behavioral, or emotional functioning, the comorbidities can negatively affect patients' quality of life more than tics do (Bernard et al. 2009; Carter et al. 2000; Eddy et al. 2011b). Similarly, parents of children with tics reported that non-tic-related symptoms are more problematic than tics themselves (Stiede et al. 2018). A large clinical follow-up study of children and adolescents with TS showed an age-related decline in tics, ADHD, and OCD during adolescence, although other symptoms, such as sleep disturbance, remained (Groth et al. 2017). Keeping in mind these comorbidities and their adverse consequences is important, and continuous assessment for them is warranted.

4.1.1 Attention-deficit hyperactivity disorder

Attention-deficit hyperactivity disorder is characterized by inattentiveness, hyperactivity, and impulsivity that interferes with functioning or development. The average prevalence of ADHD in patients with TS is about 50%–60% (within the range 33%–91%), with male dominance (Comings and Comings 1987; Freeman et al. 2000; Hirschtritt et al. 2015; Spencer et al. 1998). The onset of ADHD symptoms usually precedes the onset of motor and vocal tics by an average of 2.4 years (Comings and Comings 1987; Hirschtritt et al. 2015). Disruptive behavior and functional impairment due to ADHD adversely influence academic, social, and family functioning (Sukhodolsky et al. 2003). Compared to pure TS, patients with TS and ADHD experience more deficits in planning, working memory, inhibitory function, and visual attention (Termine et al. 2016). A heritability analysis involving individuals from affected sibling-pair families did not find significant genetic correlation between TS and ADHD, which suggests that high rates of ADHD in individuals with TS could be a result of increased but separate parental transmission of TS and ADHD susceptibility (Mathews and Grados 2011). A case-control family study showed that ADHD and TS were not necessarily alternate manifestations of a single underlying genetic cause, but an increased risk of ADHD and TS in affected families may suggest an overlap in neurobiology and pathophysiology (Stewart et al. 2006). A GWAS also suggested modest shared etiological overlap between ADHD and TS (Brainstorm Consortium 2018).

In the past, the use of stimulants for patients with tics was not recommended. Many clinicians still worry that using stimulants for the treatment of ADHD in patients with tics may make their tics worse. However, substantial evidence has dispelled the idea that stimulants are contraindicated in children with tics (Kurlan

2002). An observational study of children and adolescents with ADHD demonstrated that treatment with stimulants did not affect the course of tics (Spencer et al. 1999). A randomized, placebo-controlled trial of children with ADHD did not show that methylphenidate increased tics in children with or without preexisting tics (Law and Schachar 1999). A large randomized control trial involving children with TS and ADHD demonstrated a small but significant improvement of tics with methylphenidate (Tourette's Syndrome Study Group 2002). Another study replicated the finding that methylphenidate did not worsen tic symptoms (Bloch et al. 2009b). A single dose of dexamethylphenidate transiently improved tic severity in a double-blind study (Lyon et al. 2010). Thus, clinicians treating patients with tics and ADHD can use stimulants of the central nervous system for the treatment of ADHD symptoms.

4.1.2 Obsessive-compulsive disorder

Obsessions are intrusive and unwanted images or thoughts that occur repetitively, and compulsions are behaviors that are performed to reduce the obsession or relieve obsession-related anxiety. The diagnosis of OCD requires OCD symptoms that are time-consuming (at least 1 hour per day) or cause significant clinical distress or social or occupational functional impairment (American Psychiatric Association 2013). Lifetime prevalence rates of OCD in patients with TS are estimated to be 30%–50% (Hirschtritt et al. 2015; Lombroso and Seahill 2008), whereas the general prevalence of OCD among adults is 1%–3% (Adam et al. 2012; Ruscio et al. 2010). The OCD symptoms in patients with TS usually begin within a few years after the onset of tics (Ferrão et al. 2009; Hirschtritt et al. 2015; Holzer et al. 1994). As TS and OCD can occur in clusters in families, a shared genetic architecture has been suggested, but a possible different underlying genetic susceptibility for TS and OCD compared with OCD alone has also been suggested (Browne et al. 2015; Yu et al. 2015).

Obsessive-compulsive disorder and TS have some common characteristics, such as a chronic waxing and waning course, premonitory phenomena preceding movement, and repetitive behavior (Ferrão et al. 2009; Worbe et al. 2010). Interestingly, obsessive-compulsive behaviors of TS differ somewhat from those of pure OCD. Contamination fears and negative thoughts (e.g., something going wrong, becoming sick, or something bad happening) are more prevalent in patients with pure OCD than in patients with TS and OCD (Eapen et al. 1997). In contrast, patients with TS tend to have compulsions such as counting, checking, ordering, arranging, touching, and hoarding as well as aggressive, sexual, religious and symmetry obsessions (Leckman et al. 1994a). Moreover, “just right” perception, where patients need to perform the same action repeatedly until they feel “just right,” is characteristic of TS with OCD (Leckman et al. 1994b). The “just right” sensation can be distinguished from other premonitory urges in that the “just right” perception relates to a mental phenomenon (e.g., a want), whereas the

premonitory urge involves a bodily sensation (e.g., an itch) (Leckman et al. 1994b).

Trichotillomania is characterized by recurrent pulling out of hair and can be seen in both TS and OCD. Due to its repetitive nature, Trichotillomania is generally considered part of the OCD spectrum, but Trichotillomania has some common features with TS. Trichotillomania is typically preceded by urges but not obsessions and can be treated similarly to tics (e.g., antipsychotics and habit-reversal training) (Lamothe et al. 2020). Similarly, skin picking is diagnosed separately in DSM 5, but also has long been considered a complex tic (Leckman et al. 1989).

4.1.3 Anxiety and depression

Anxiety and depression each occur in about 30% of patients with TS (Hirschtritt et al. 2015). The high-risk age period begins around 4 years for anxiety disorders and around 7 years for mood disorders (Hirschtritt et al. 2015). Comorbid depression positively correlates with tic severity (Rizzo et al. 2017). Tourette syndrome patients with depression have a positive family history of depression (Rizzo et al. 2017). About 10% of youth with tic disorders experience suicidal thoughts and attempts, which often occur in the context of anger and frustration (Johnco et al. 2016; Storch et al. 2015). Although there is no correlation between suicidal ideation and tic severity, the presence of anxiety and depression increases the risk of suicidality in patients with tic disorders (Johnco et al. 2016). In a large epidemiological cohort study from the Swedish National Patient Register, adults with TS had about four-fold higher risk of both suicidal attempt and death (Fernández de la Cruz et al. 2017). It is therefore important to assess depression and anxiety symptoms, especially in patients with a positive family history of depression. In clinics, attention is often focused more on addressing the comorbid symptoms than the tics themselves.

4.1.4 Other neuropsychological symptoms

Eating disorders such as anorexia nervosa and bulimia nervosa are present in 2% of patients with TS, with female predominance and onset in adolescence (15–19 years old) (Hirschtritt et al. 2015). Retching and vomiting may be symptomatic of tics if they occur alongside other tics and are accompanied by signs of tics such as suppressibility and premonitory urges (Rickards and Robertson 1997). However, medications for the treatment of TS symptoms, such as selective serotonin reuptake inhibitors and alpha-2 adrenergic agonists, can cause retching and vomiting (Rickards and Robertson 1997). Thus, clinicians caring for TS patients with gastrointestinal symptoms need to be aware of these possible causes.

Disruptive behaviors and rage episodes including explosive anger, temper outbursts, irritability, and aggressiveness are reported in 25%–70% of TS patients

(Budman et al. 2003). The rage symptoms seem to be more closely correlated with the presence of other comorbid symptoms such as ADHD, OCD, and depression rather than tic severity (Budman et al. 1998). Aggressive obsessions and compulsions, impulse dysregulation such as episodic rages, and risk-taking behaviors correlate with self-injurious behavior in TS (Mathews et al. 2004). Oppositional defiant disorder is reported in approximately 11%–54% of TS patients and conduct disorder in approximately 6%–20% (Eapen and Robertson 2008).

Children with tics are at higher risk of being bullied and experiencing difficulties in socializing due to the social stigma (Cox et al. 2019). Difficulties in school or the workplace often lead to discrimination, which may lower their self-esteem (Cox et al. 2019). Poor self-perception and self-esteem are also related to the presence of comorbid psychiatry symptoms such as OCD, ADHD, and anxiety disorder (Silvestri et al. 2018). The quality of life of patients with tic disorders is tied to their self-perception, and so clinical treatment should focus on their self-concept and self-esteem (Silvestri et al. 2018). Schizotypal personality disorder occurs in 15% of patients with TS and is associated with the presence of multiple psychiatric comorbidities (Cavanna et al. 2007). Although patients with TS occasionally exhibit socially unacceptable behaviors, they rarely commit criminal acts (Jankovic et al. 2006).

4.1.5 Sleep disorders

Sleep disorders occur in 64% of patients with TS (Ghosh et al. 2014). Even after adjusting for potential confounding factors for sleep disorders, such as obesity, asthma, allergic rhinitis, anxiety, and depression, TS has been found to independently increase the risk of difficulty with sleep initiation and sleep maintenance, parasomnia, abnormal arousal, and excessive daytime sleepiness (Ghosh et al. 2014; Jankovic and Rohaidy 1987; Lee et al. 2017; Ricketts et al. 2018). A polysomnography study demonstrated that both motor and vocal tics are observable during all stages of sleep (Jankovic and Rohaidy 1987). The likelihood of sleep disturbance is higher when ADHD or OCD is present (Kirov et al. 2007; Mol Debes et al. 2008). Moreover, sleep disturbances themselves can aggravate tic symptoms in the daytime (Kirov et al. 2007). Treatment of sleep problems in patients with tics may therefore reduce the severity of tics as well as improve the sleep disorders themselves.

4.1.6 Headache

A headache is a common symptom in TS. A prospective questionnaire interview study showed that about 55% of children and adolescents with TS experience headache symptoms (Ghosh et al. 2012). Migraine has been reported in about 17%–27% of patients with TS with a mean age of 11.9 years (Barabas et al. 1984;

Ghosh et al., 2012; Kwak et al. 2003b). This prevalence is higher than that of general school-aged children (2%–10%) and adults (10%–13%) (Barabas et al. 1984; Kwak et al. 2003b). Tension-type headache is also commonly seen in patients with tics. The interview study also reported that 28% of children and adolescents with TS had tension-type headaches, and the prevalence of tension-type headache is more than five times higher in tic patients than in the general pediatric population (Ghosh et al. 2012). The exact mechanism of headaches in TS has not been elucidated, but a defect in serotonin metabolism has been suggested for migraine and tension-type headaches (Ghosh et al. 2012; Kwak et al. 2003b). The GWAS showed significant positive correlations between migraine and TS (Brainstorm Consortium 2018).

4.1.7 Learning disability

It is widely accepted that tic disorders do not affect intelligence and that most children with tics have normal or above normal intelligence. Although there is no evidence of memory or learning impairment in patients with TS (Channon et al. 2003), various factors such as tic severity, use of medication for tics, executive dysfunction, and coexisting ADHD, OCD, or other psychological illnesses can affect performance in school (Brand et al. 2002; Singer et al. 1995). In a case-control study comparing children with TS only to children with TS and ADHD or highly suspected ADHD, learning disability was present in 23% of the children but only in those with TS with ADHD or highly suspected ADHD, not in those with TS only (Schuerholz et al. 1996). Patients with TS and tic disorders who seek treatment are more likely to underachieve academically across all educational levels, even after accounting for various confounders and comorbidities (Pérez-Vigil et al. 2018). Detecting and addressing their difficulties at school (e.g., providing extra time to finish tasks, establishing a private space to release tics) is warranted to support their educational needs and enable them to reach their academic potential (Pérez-Vigil et al. 2018).

4.2 Physical examination

Although a complete physical examination with direct clinical observation is important in diagnosing neurological disorders, the neurological examination is normal in children with a tic disorder, except for the tics themselves (Dooley et al. 2003). The normal examination is important for ruling out secondary causes of tics (such as Huntington's disease). Interestingly, patients with tics may subconsciously suppress their tics in the clinic (Goetz et al. 2001). Thus, it is wise to ask their guardians to video record their tics at home to understand their characteristics and severity.

5 Evaluation (Labs/imaging)

Tic disorders are clinical diagnoses based on clinical history and observation. No diagnostic laboratory or neuroimaging testing exists. Testing has not played an important role in tic management (Dooley et al. 2003). If unusual historical or examination features suggest secondary tic disorders, evaluations with blood, neuroimaging, or electrophysiological testing are warranted.

6 Treatment and Management

Treatment and management of tic disorders begin with an assessment of tic frequency and severity and the presence of comorbid symptoms. To assess the frequency and severity of tic symptoms, the Yale Global Tic Severity Scale (YGTSS) is often used in clinics (Martino et al. 2017). The YGTSS is a semi-structured clinical rating instrument for the assessment of tic severity in children, adolescents, and adults (Leckman et al. 1989). It is important to identify whether tics or comorbidities could cause functional or emotional impairment. Unless tics are bothersome to patients, supportive care, reassurance, and education of the patient, family, and school are usually sufficient. The discussion should cover the diagnosis, the natural history of the disorder, activities or conditions that could worsen their tics, comorbidities, and indications for treatment. It is also important to debunk myths and misconceptions promulgated by stereotyped social media images. For example, many guardians and patients believe that TS is caused by stress or neglect; that tics will always progress to non-stop motor tics and socially inappropriate behaviors such as cursing; and that individuals with tics are intellectually impaired and cannot lead normal lives. In the U.S., the Tourette Association of America, a non-profit voluntary organization, and the Centers for Diseases Control and Prevention provide comprehensive materials to guardians and patients about TS and tic disorders in a variety of languages.

Pharmacological tic-suppressing treatment and behavioral therapy should be considered when tics cause physical, emotional, or social impairment (e.g., musculoskeletal injury, peer relation difficulty such as bullying, disruptive tic behaviors, low self-esteem, and difficulty in conducting physical or academic activities). The goal of the treatment is to lessen the severity of the tics to improve the patient's quality of life.

6.1 Behavioral therapy

The American Academy of Neurology practice guideline recommendations summary mentions a form of behavioral therapy as the first-line treatment for tics (Pringsheim et al. 2019). Tic-suppression-based behavioral interventions consist of exposure and response prevention and habit-reversal therapy or its descendant

comprehensive behavioral interventions for tics (CBIT) (Specht et al. 2014). Exposure and response prevention consists of repeated, prolonged exposure to stimuli that tend to induce tics and practice to resist tic behavior (Verdellen et al. 2004). Theoretically, patients could learn to habituate to the unpleasant tic-provoking sensations, thus resulting in tic reduction (Hoogduin et al. 1997). Habit-reversal therapy consists of awareness training and competing-response training to encourage tic suppression for long periods of time (Piacentini et al. 2010). Awareness training consists of self-monitoring tics and identifying early signs or warning signs, such as the premonitory urge. Competing-response training involves engagement in an active voluntary response that is incompatible with tics, such as tensing muscles antagonistic to tic-related muscles (Himle et al. 2006; Piacentini et al. 2010). These two forms of training can be effective for both motor and vocal tics. In clinical practice, patients and therapists first determine a tic hierarchy from most to least distressing and then first address the most distressing tic (Piacentini et al. 2010). With practice, patients will be able to perform the competing response more effectively and efficiently (Piacentini et al. 2010).

The most widely accepted behavioral therapy for tic disorders is CBIT, which consists of habit reversal therapy, psychoeducation, functional intervention, and relaxation training (Fründt et al. 2017; Pringsheim et al. 2019). It is safe, has no serious adverse effects, and can be applied to children and adults to help to reduce the severity of tics (Piacentini et al. 2010; Wilhelm et al. 2012). Although these therapies can eventually diminish the urges and decrease tic frequency and severity, finding a trained therapist can be difficult. Recently, internet-based training programs have been made available to solve this issue. For example, “TicHelper” (<https://www.tichelper.com>) is an interactive, self-administered online CBIT program for school-age children. It is an 8-week program designed to teach tic-management skills where children and guardians can learn about tics, such as how to reduce tic triggers and employ tic-blocking techniques (Conelea and Wellen 2017). “TicTrainer” (<https://tictrainer.com>) is a free but untested internet-based tic-suppression training program consisting of a reward-enhanced exposure and response prevention strategy. Users attempt to suppress their tics to gain rewards, as if they were playing a video game. For example, they earn points for tic suppression, and the longer they suppress their tics, the more points they earn (Black and Black 2017). Internet-based behavioral therapy gives patients and guardians more access to evidence-based therapies and may be effective in the long run (Andrén et al. 2019).

6.2 Other non-pharmacological treatment

Various complementary and alternative medicines have been used for the treatment of tics, including prayer, vitamins, massage, dietary or nutritional supplements (e.g., the B vitamins, vitamins C, D, and E, calcium, magnesium, Coenzyme Q10, fish oil), chiropractic manipulations, meditation, diet, yoga, acupuncture, hypnosis, homeopathy, and biofeedback (Kompolti et al. 2009; Kumar et al.

2018). Although these have been reported to be effective to some extent, there have been no randomized control studies to establish dosing, safety, and efficacy (Kumar et al. 2018). Acupuncture may be effective for the treatment of tics for a short period, but the evidence is limited due to biases (Yu et al. 2016). Since patients often pursue complementary and alternative medicines without informing their physicians, the treating physician needs to ask about these therapies (Kopoliti et al. 2009).

6.3 Pharmacological treatment

Pharmacological treatment should be considered when behavioral interventions fail or are not available (e.g., lack of access to behavioral therapies, including expense, or patient factors such as age, cognition, or willingness to participate) or when patients exhibit severe, violent tics that need immediate treatment. Before starting patients on a course of medication, clinicians must explain the purpose and set a realistic goal—that is, to reduce the severity and frequency of tics to the extent that they no longer bother the patients or cause significant problems.

Various therapeutic algorithms have helped clinicians choose medicines for the treatment of tics. In general, there are two tiers of medicines, based on tic severity. The first-tier medicines are for mild tics, and the second-tier medicines are for severe tics or tics that are resistant to the first-tier medicines (Jankovic 2020; Quezada and Coffman 2018; Singer 2019). As a rule, the medicines should be started on a low dose with gradual titration until they become effective. Once the symptoms subside to such a degree that the tics are no longer bothersome, physicians should discuss weaning off the medicines with patients and caregivers. The trial of weaning off the medicines should be undertaken only when the patient is mentally and physically healthy and does not anticipate any stressful situations or events.

6.3.1 First-line medicines

Medicines in this category are non-dopaminergic agents that are mildly to moderately effective in tic suppression and do not have severe adverse effects. The typical medicines in this category are alpha-2-adrenergic agonists such as clonidine and guanfacine (Eddy et al. 2011a). As the alpha-2-adrenergic agonists are useful for the treatment of ADHD in children and adolescents (Kollins et al. 2011; Ming et al. 2011), both tics and ADHD symptoms may improve. Clonidine is frequently used for the treatment of tics. The Tourette's Syndrome Study Group conducted a large randomized control trial involving children with TS and ADHD to investigate the efficacy of clonidine and methylphenidate for tics and ADHD (Tourette's Syndrome Study Group 2002). The children who took both clonidine and methylphenidate showed the most improvement, followed by those who took only clonidine. As well as an oral preparation of clonidine, an adhesive transder-

mal patch is available for the treatment of high blood pressure. A randomized control study of children with tic disorders showed its efficacy and safety in tic treatment (Du et al. 2008). The recommended starting dose of clonidine is 0.025–0.05 mg/day, and it should be slowly titrated up to a therapeutic range of 0.1–0.3 mg/day (Pringsheim et al. 2012; Roessner et al. 2011b). The maximum total daily dose is 0.4 mg/day, divided up to 4 times a day with the highest single dose being 0.2 mg (Qasaymeh and Mink 2006). The side effects of clonidine include sedation, drowsiness, lightheadedness, tiredness, irritability, dry mouth, bradycardia, and hypotension. Although electrocardiogram monitoring is not necessary (Gutgesell et al. 1999), close monitoring of blood pressure and heart rate is essential. Due to the side effect of sleepiness, clonidine may be useful for patients with tics who have difficulty with sleep initiation.

Guanfacine is another alpha-2 adrenergic agonist that has been used for the treatment of high blood pressure and ADHD. Its therapeutic effect for tics has been reported in open-label studies of children with TS and ADHD (Boon-yasidhi et al. 2005; Chappell et al. 1995) and a placebo-control clinical trial of children with TS and ADHD (Scahill et al. 2001). The adverse effects are similar to those of clonidine, such as fatigue, drowsiness, dry mouth, headache, and irritability (Murphy et al. 2017). Guanfacine acts on alpha-2 receptors of neural cells more selectively than clonidine does, and it has a longer half-life and less severe adverse effects such as sedation and dizziness (Sharma and Couture 2014). Thus, guanfacine is often more favored than clonidine. However, a randomized double-blind study of the extended-release formulation of guanfacine in children with moderate-to-severe chronic tic disorder did not show a clinically meaningful effect for tic suppression (Murphy et al. 2017). The recommended starting dose of guanfacine is 0.5–1.0 mg/day, and it should be titrated slowly up to a therapeutic range of 1.0–4.0 mg/day (Pringsheim et al. 2012; Roessner et al. 2011b).

Based on a hypothesis that inhibitory GABA signaling dysfunction in the basal ganglia underlies the pathology of TS (Jackson et al. 2015), GABAergic medications such as antiepileptic drugs and baclofen have been used for the treatment of tics. Evidence of the efficacy of these medicines is not as robust as that of alpha-2 adrenergic agonists, but these medicines can be used as a monotherapy or as add-on therapy in the treatment for tics.

Topiramate is a broad-spectrum antiepileptic drug that enhances GABAergic activity and inhibits kainate/AMPA glutamate receptors (Lyseng-Williamson and Yang 2007). An open-labeled study and a randomized double-blind study of children and adolescents with TS showed moderate efficacy and a statistically significant reduction in the YGTSS (Jankovic et al. 2010b; Kuo and Jimenez-Shahed 2010). The adverse effects of topiramate noted in the study included headache, diarrhea, abdominal pain, drowsiness, cognitive slowing, and kidney stones (Jankovic et al. 2010b). The starting dose is 25 mg/day, and it should be titrated up gradually to 50–200 mg/day depending on efficacy and tolerability (Jankovic et al. 2010b).

Levetiracetam is an antiepileptic medicine that enhances GABA inhibition of neuronal circuits (Palma et al. 2007). Open-label studies of children and adolescents with TS showed statistically significant improvement of tic symptoms (Awaad et al. 2005; Fernández-Jaén et al. 2009). Their behavioral and school performance also improved with levetiracetam (Awaad et al. 2005). On the other hand, randomized double-blind studies of children and adults with TS showed no reduction in tic severity or improvement in behavioral scores (Hedderick et al. 2009; Smith-Hicks et al. 2007). The adverse reactions include irritability and somnolence. The initial dose of levetiracetam is 20 mg/kg/day or 250 mg/day (Awaad et al. 2005; Fernández-Jaén et al. 2009). The dose is increased gradually up to 30–40 mg/kg/day, with a maximum dose of 60 mg/kg/day or 2,000 mg/day (Awaad et al. 2005; Fernández-Jaén et al. 2009).

Clonazepam is a benzodiazepine that has been used for the treatment of seizures and panic attacks. It acts on benzodiazepine receptors, increasing the effect of GABAergic transmission (Jenner et al. 1986). A case report of a 13-year-old boy with TS showed that his tics improved with clonazepam (Kaim 1983). A single-blind study of patients with TS who had high ratios of red blood cells to plasma showed more response with clonazepam than haloperidol (Merikangas et al. 1985).

Baclofen is a GABA B receptor agonist and has been used for the treatment of spasticity. A large cohort open-label study of children with TS revealed a significant reduction in the severity of tics (Awaad 1999). A double-blind, placebo-controlled crossover trial of children with TS demonstrated a reduction in tic severity, as measured by the YGTSS, although the reduction was not statistically significant (Singer et al. 2001). Common side-effects are sedation and drowsiness (Awaad 1999). The starting dose is 10 mg/day, and it can be increased gradually by 10 mg/day weekly, depending on the patient's symptoms, up to 80 mg/day (mean 30 mg/day) (Awaad 1999).

6.3.2 Second-line medicines

Medicines in this category are dopamine receptor blocking agents (DRBA) (e.g., typical and atypical neuroleptics). Abnormal dopaminergic activity is considered to be involved in the mechanism of TS (Singer et al. 1982). Specifically, D2 receptor blocking agents reduce tic severity by about 70% (Roessner et al. 2011b). They are more effective in tic suppression than the first-line medicines but cause more adverse effects such as sedation, metabolic syndrome (e.g., obesity, insulin resistance, hypertension, and dyslipidemia), akathisia, dystonia, or rigidity-bradykinesia (Lieberman 2004; Stroup and Gray 2018).

Cardiovascular adverse effects such as torsades de pointes, QTc prolongation, myocarditis, and cardiomyopathy can be life-threatening (Howell et al. 2019; Stoner 2018). Antipsychotic-induced tardive dyskinesia (TD) is also common in schizophrenia affecting approximately 21% of patients with schizophrenia receiv-

ing atypical neuroleptics and 30% receiving typical neuroleptics (Widschwendter and Hofer 2019). However, TD is apparently quite rare in TS. The classic symptoms of TD are involuntary, repetitive hyperkinetic movement around the mouth (e.g., chewing, protrusion of the tongue, jaw movements, lip-smacking, or puckering) (Schooler and Kane 1982). The dyskinesia usually emerges insidiously and can occur after short-term or long-term use of neuroleptics (Waln and Jankovic 2013). TD can be distinguished from tics by the time course and by several other features, including that TD is usually rhythmic at 0.5-2 Hz, does not include premonitory phenomena, and is perceived by the patient as truly involuntary. The DSM-5 describes TD as medication-induced dyskinesia that occurs in the following conditions: (1) during exposure to a DRBA for at least three months, or one month in patients aged 60 years or older; (2) within four weeks of withdrawal from an oral medicine or within eight weeks from a depot medication. The symptoms should persist for at least one month after discontinuation of an offending agent (American Psychiatric Association 2013). Some experts argue that TD can occur within one year after exposure to DRBAs (Waln and Jankovic 2013). By definition, TD symptoms persist for at least one month after the discontinuation of medicine (Cornett et al. 2017). A rapid reduction or sudden discontinuation of the medicine may lead to transient worsening of dyskinesia, known as withdrawal dyskinesia (Karaş et al. 2016; Widschwendter and Hofer 2019). Slow and gradual tapering of the offending medication over a period of weeks or months is recommended for patients who develop TD and do not have a psychiatric illness (Ricciardi et al. 2019). Although many patients with TD showed some improvement within the first year of discontinuation of neuroleptic, the chance of complete remission has been reported to be low in both psychiatric and non-psychiatric patients (Glazer et al. 1990; Zutshi et al. 2014).

The medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of tics are haloperidol, pimozide, and aripiprazole. Haloperidol is a D2 receptor antagonist and was reported to be effective for tic treatment in the early 1960s (Chapel et al. 1964; Rickards et al. 1997). A case-series study (Shapiro et al. 1973) and a double-blind placebo-controlled study (Ross and Moldofsky 1978) demonstrated a similar therapeutic effect. A double-blind crossover study of haloperidol, pimozide, and a placebo revealed that haloperidol was slightly more effective than pimozide (Shapiro et al. 1989). However, a placebo-controlled double crossover study of children and adolescents with TS showed that haloperidol failed to provide significant benefit in tic reduction and was inferior to pimozide in tic suppression (Sallee et al. 1997). Furthermore, haloperidol causes more side-effects than pimozide, such as lethargy and extrapyramidal side-effects (Ross and Moldofsky 1978; Sallee et al. 1997; Sandor et al. 1990). Haloperidol is therefore not regarded as a preferred treatment for tic suppression but instead is recommended for patients who have not responded to other tic-suppressing medicines (Budman 2014). The starting dose is usually 0.5 mg/day, and it should be titrated gradually by 0.25–0.5 mg every 5–7 days. The typical dose ranges from 2 mg to 10 mg daily (Budman 2014).

Pimozide is a potent DRBA and has been reported to be effective in tic suppression in clinical studies (Bruggeman et al. 2001; Gilbert et al. 2004; Regeur et al. 1986; Shapiro et al. 1983). A prospective and double-blind clinical cohort study of children with TS demonstrated that pimozide was effective in the short and long term (Tourette's Syndrome Study Group 1999). Arrhythmias such as QT prolongation and decreased blood pressure have been associated with patients receiving pimozide (Flockhart et al. 2000; Gulisano et al. 2011; Shapiro and Shapiro 1984; Shapiro et al. 1989). The starting dose is usually 0.05 mg/kg daily, and it should be gradually increased to 0.2 mg/kg, not exceeding 10 mg/day (Rogers et al. 2012). Because coadministration of potent cytochrome P450 (CYP) 2D6 inhibitor (e.g., sertraline) could increase pimozide concentration (Alderman 2005) and the arrhythmogenic side-effects of pimozide are concentration-dependent (Drolet et al. 2001), the FDA recommends CYP2D6 genotyping (Rogers et al. 2012). In poor CYP2D6 metabolizers, the maximum dose should not exceed 0.05 mg/kg/day, and titration should be no sooner than every 14 days (Rogers et al. 2012).

Aripiprazole is an atypical neuroleptic that is approved by the FDA for the treatment of tics. It is a dopamine-serotonin partial agonist, acting as a partial D2, D3, and D4 receptor agonist, as well as a partial 5-HT1A, 5-HT2A, and 5-HT2C agonist (Shapiro et al. 2003). A large multicenter, double-blind, randomized placebo-controlled study of children and adolescents with TS demonstrated that aripiprazole was superior to placebo in the reduction of tics with good tolerability (Yoo et al. 2013). Compared to pimozide, aripiprazole has a safer cardiovascular profile (Gulisano et al. 2011). The starting dose of aripiprazole is usually 1.25–2.5 mg/day, with gradual titration from 2.5 mg/day to 20 mg/day divided into two doses according to tic severity and tolerability (Budman et al. 2014; Cox et al. 2016).

Risperidone is frequently used for the treatment of tics, although it is not FDA-approved for this indication. It acts as a D2 and 5-HT2 receptor antagonist (Bruun and Budman 1996). Risperidone may effectively reduce aggressive behavior as well as tic severity in patients with TS (Sandor and Stephens 2000). An open-label trial (Bruun and Budman 1996) and a randomized, double-blind, placebo-controlled trial (Scahill et al. 2003) of patients with TS showed that risperidone reduces tic severity. A randomized, double-blind, parallel-group clinical trial of children with TS investigating the efficacy and tolerability of risperidone and clonidine demonstrated that risperidone was as effective as clonidine for the treatment of tic symptoms (Gaffney et al. 2002). The adverse effects of risperidone include sedation, extrapyramidal symptoms (e.g., acute dystonic reactions, parkinsonism, and akathisia), orthostatic hypotension, hyperprolactinemia, gynecomastia, and weight gain. The starting dose is 0.25 mg daily, and it should be increased slowly every 5–7 days up to 0.25–4.0 mg daily (Budman 2014).

Olanzapine is an atypical neuroleptic with a multiple-receptor-blocking profile including D1–D4, 5-HT, muscarinic, and histaminergic antagonists (Bymaster et al. 1996), and it has also been investigated for the treatment of tics. A clinical trial

of children with TS showed that olanzapine was effective for tic suppression and aggression but significant weight gain was noted (Stephens et al. 2004). Due to its important side-effects such as weight gain and sedation or drowsiness, olanzapine must be used cautiously in children (McCracken et al. 2008). Olanzapine is started at 2.5–5.0 mg/day and titrated every 5–7 days to a maximum of 30 mg/day (Budman 2014).

Ziprasidone is an atypical neuroleptic and acts mainly as a 5-HT and D2 receptor antagonist and blocks other neurotransmitters (Huys et al. 2012). A randomized, double-blind, placebo-controlled trial of children and adolescents with TS showed that ziprasidone reduced tics significantly and was tolerated well (Sallee et al. 2000). Unlike other atypical neuroleptics, ziprasidone does not appear to cause weight gain and extrapyramidal symptoms but is associated with a dose-dependent QTc interval prolongation (Keck et al. 2001). Thus, patients with cardiac disease should avoid ziprasidone therapy. Ziprasidone is started at 5–10 mg/day and titrated slowly every week to a maximum of 40 mg/day (Budman 2014).

Ecopipam is a selective D1 receptor agonist and has drawn attention as a treatment for tics. A randomized, placebo-controlled crossover study of children and adolescents with TS showed that ecopipam reduced tics significantly and was well tolerated (Gilbert et al. 2018b). Adverse events included gastrointestinal symptoms, decreased appetite, fatigue somnolence, headache insomnia, rash and nasopharyngitis, but no serious side effects were reported.

Compared to neuroleptics that block dopamine receptors, dopamine-depleting agents that deplete presynaptic dopamine by blocking the vesicular monoamine transporter type 2 are safer with little or no risk of TD and have been used in the treatment of movement disorders such as chorea, TD, and tics (Jankovic 2016). Tetrabenazine is an FDA-approved medicine for the treatment of chorea associated with Huntington's disease. Open-label clinical studies of patients with TS showed that tetrabenazine improved their tics and TS-related symptoms (Kenney et al. 2007; Porta et al. 2008). Side-effects of tetrabenazine include drowsiness, sleepiness, akathisia, parkinsonism, and depression, which can be controlled by adjusting the dose (Kaur et al. 2016). Tetrabenazine is usually reserved for patients with severe tics who did not respond to or cannot tolerate other tic medicines. Importantly, tetrabenazine carries a black box warning regarding possible deterioration of an already present depression and should be used cautiously (Kaur et al. 2016). Unfortunately, initial trials of two tetrabenazine derivatives in TS failed to show efficacy (the results are not published but the information is available from: <https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-announces-topline-data-phase-iib-t-force>; <https://clinicaltrials.gov/ct2/show/results/NCT03452943>).

6.4 Other treatment

Aside from oral pharmacological treatment, botulinum toxin injections have been used in the treatment of spasticity and movement disorders (Camargo and Teive 2019). Botulinum toxin's mechanism of action is to inhibit the release of neurotransmitters (e.g., acetylcholine) from the presynaptic nerve terminal by cleaving soluble N-ethylmaleimide-sensitive factor attachment protein receptor proteins, which are essential for presynaptic vesicle fusion (Jankovic 2004). An injection of botulinum toxin into muscles that cause tic movements improves tic symptoms but also reduces the premonitory urge (Kwak et al. 2000; Marras et al. 2001). Similarly, the injection into the vocal cords also improves vocal tics and the premonitory urge (Porta et al. 2004). Treatment with botulinum toxin should be considered in patients with severe self-injurious motor tics (e.g., repetitive cervical extension) to prevent the progression of disabling myelopathy (Krauss and Jankovic 1996).

Deep brain stimulation (DBS) is a neurosurgical procedure to implant a device called a neurostimulator to deliver electrical stimulation to a targeted brain region and may be a promising treatment for patients with tics (Martinez-Ramirez et al. 2018). Reported targets for DBS include the thalamus, globus pallidus internus, globus pallidus externus, anterior limb of the internal capsule, and nucleus accumbens (Viswanathan et al. 2012). The prospective International Deep Brain Stimulation Database and Registry demonstrated that the overall adverse event rate was 35.4% including intracranial hemorrhage (1.3%), infection (3.2%), and lead explantation (0.6%) (Martinez-Ramirez et al. 2018). Dysarthria (6.3%) and paresthesia (8.2%) were the most common stimulation-induced adverse effects (Martinez-Ramirez et al. 2018). Further studies are needed to identify the optimum target, the benefits and risks, indications, timing for the procedure, and stimulation parameters (Coulombe et al. 2018).

7 Prognosis and Outcomes

It was once widely believed that almost all tics would disappear within a few months of the first onset. However, epidemiological data for the clinical course of the new onset of tics are sparse. Conducting a follow-up study of Provisional Tic Disorder is difficult, as many patients do not seek medical help for their tics unless they find them bothersome (Khalifa and von Knorring 2005). A clinical follow-up study of children with new-onset of tics that began within the six months after the first tics showed that their tics persisted 12 months after the new onset, but most of the children were not bothered by their tics (Kim et al. 2019). This discrepancy between the clinical experience and the result of the study was probably due to the tics becoming so subtle after 12 months that the patients and their caregivers were unaware of them or no longer felt the need for clinical attention.

Most patients with TS follow a similar clinical course with a reduction of tic severity over time (Leckman et al. 1998). Tic symptoms usually reach their highest severity around age 10 years and improve during adolescence (Bloch and

Leckman 2009). Although tics are still present on direct examination in 88%–100% of adults with a TS diagnosis in childhood or adolescence (Black et al. 2020), about 33%–47% of patients with TS report being completely tic free, less than 50% have mild tics, and less than 25% have moderate or severe tics in adulthood (Bloch and Leckman 2009; Burd et al. 2001; Leckman et al. 1998). In other words, most patients with TS are no longer bothered by tics in adulthood. This fact can be welcome information for patients and guardians who are anxious about the prognosis of tic disorders (Bloch et al. 2006).

Although TS and chronic tic disorders were associated with higher risk of premature death, irrespective of the presence of comorbidities such as ADHD, OCD, and substance abuse, in a prospective cohort study (Meier et al. 2017), adults with TS reported good psychosocial functioning, attainment of social milestones such as graduating from school, securing a job, and getting married, and high quality of life (Goetz et al. 1992; Lowe et al. 2018). As many people still have misconceptions about tic disorders (e.g., tics are due to psychological issues, or individuals with tics cannot lead normal lives), providing anticipatory guidance at the time of the diagnosis of TS can reassure patients and their families (Lowe et al. 2019).

Various studies including genetic studies, neuropsychological testing studies, and neuroimaging studies have revealed only a few predictive factors of future tic disorders (Bloch et al. 2006). A clinical interview study of adults who had tics in childhood showed that tic severity in childhood and the presence of coprolalia were not necessarily predictors of adulthood tic severity (Goetz et al. 1992). In contrast, another clinical prospective longitudinal study of adults who had tics in childhood showed that severity of tics in late childhood was associated with tic severity in early adulthood (Bloch et al. 2006). Comorbid symptoms such as ADHD, OCD, and depression persist into adulthood and require close monitoring (Groth et al. 2017; Jankovic et al. 2010a).

8 When to Refer and Admit

Given the benign outcome and prognosis of tics, patients usually do not need to be referred to specialists. Adequate education for patients, family members, and schools is sufficient. If tics are severe and bothersome enough to affect quality of life, activities, and self-esteem and cause significant social, emotional, and physical impairments, it is appropriate to refer the patient to a specialist. Depending on what problems most bother the patient, more than one specialist referral may be needed, including pediatric neurologists, psychologists, psychiatrists, and behavioral therapists who have had training in CBIT.

Although hospital admission due to tics is very rare, about 5% of patients with TS who were referred to a movement disorder clinic exhibited life-threatening tics, known as “malignant TS” (Cheung et al. 2007). Life-threatening and dangerous self-injurious tic behaviors such as hyperextension of the neck are indications

for hospital admission (Cheung et al. 2007). If patients have suicidal ideation, psychiatric hospital admission will often be warranted. Treatment for malignant TS is challenging. The first-line and second-line tic medicines are used, but may not be effective. Behavioral therapy or CBIT may be used with some benefit. For cases refractory to behavior therapy and medication, DBS of the globus pallidus interna or centromedial thalamus may be an option; DBS has been demonstrated to improve tics by at least 50% (Cheung et al. 2007; Johnson et al. 2019; Schrock et al. 2015). Abrupt withdrawal of neuroleptics or clonazepam may lead to severe, disabling, and continuous tics, referred to as “tic status.” Tic status may interfere with activities and sleep, can be refractory to tic-suppression medicines, and often require sedation with propofol and midazolam (Kovacs et al. 2011)

9 Prevention

There are no preventive measures for the development or progression of tics.

10. Differential Diagnosis

Various movements may resemble tics, from the common (e.g., habits, stereotypies, and mannerisms) to the abnormal (e.g., compulsion, chorea, dystonia, and myoclonus). To distinguish such movements from tics, one can confirm the presence of the premonitory urge, suppressibility, and suggestibility, as well as the phenomenology and timing of the movements.

Habits (or body-focused repetitive behaviors) are movements elicited by environmental stimuli or contexts and not performed to obtain future outcomes (e.g., nail biting, picking, thumb sucking, and hair twirling) (Robbins and Costa 2017). Stereotypies are described as repetitive, patterned, non-purposeful movements (e.g., body rocking, tapping, hand flapping, arm waving) that stop with distraction or calling the child’s name, are frequently seen in early childhood and may persist until adolescence with gradual reduction in frequency and duration (Oakley et al. 2015). They can occur in otherwise healthy children and in children with ADHD, OCD, anxiety, and autistic spectrum disorder (Martino and Hedderly 2019). Tics and stereotypies may coexist and may be differentiated by certain features. Stereotypies usually begin before the age of 3 years, which is earlier than the onset of tics, and they tend to improve during childhood (Freeman et al. 2010). Compared to tics, stereotypies are longer in duration and less variable in type and location (Freeman et al. 2010). The premonitory urge is not seen in patients with stereotypies. Stereotypies often provide a comforting, enjoyable, and pleasing experience for children, in contrast to the discomfort and distress of tics (Martino and Hedderly 2019). Reassurance and psychoeducation are usually appropriate for stereotypies. In severe cases, behavioral therapies such as habit-reversal training or

response interruption and redirection might reduce the severity and frequency of stereotypies, but pharmacotherapy is usually not effective (Katherine 2018). The use of an instructional DVD as a home-based, parent-administered behavioral therapy has been shown to reduce stereotypies by 15%–24% (Specht et al. 2017).

Mannerisms are repetitive and unusual habits or gestures unique to the individual that may seem stereotypical at times (Mulligan et al. 2003; Yung 1983). Mannerisms can be seen not only in healthy individuals but also in patients with schizophrenia with delusions (Kaufmann et al. 2018). Unlike tics, mannerisms may be goal-directed (e.g., performing a ritualistic action for luck) (Kaufmann et al. 2018; Yung 1983). Mannerisms do not require treatment.

Compulsions are repetitive behaviors (e.g., hand washing) or mental acts (e.g., praying, counting) that are performed in response to an obsession or to prevent distress (American Psychiatric Association 2013). Some complex motor tics such as touching, tapping, and knocking resemble compulsions. Clinically, compulsions are associated with specific, sometimes ritualistic rules, or are performed in response to an obsession to reduce anxiety, distress, or discomfort (Palumbo and Kurlan 2007). Unlike patients with tics, those with compulsions do not experience premonitory sensations. Compulsions and complex tics may both occur in patients but distinguishing between them can be important to guiding treatment of the most bothersome symptoms. Compulsions improve with treatments for OCD, such as behavior therapy or serotonin reuptake inhibitors.

Chorea is characterized by brief, abrupt, irregular, unpredictable, purposeless, non-stereotyped movements flowing randomly from one part of the body to another (Sanger et al. 2010). Damage or dysfunction of the interconnection between the motor cortical areas and the basal ganglia, including the caudate nucleus, putamen, globus pallidus interna and externa, and associated structures such as the subthalamic nucleus and substantia nigra, leads to deficient inhibition to the thalamus and excessive thalamocortical motor facilitation, resulting in chorea movements (Cardoso et al. 2006). The etiologies of acute chorea include autoimmune disease, infection, vascular disease, mitochondrial disease, toxins, and functional disease and those of chronic chorea include genetic, metabolic, and vascular diseases (Gilbert 2009). To differentiate between chorea and tics, it is essential to obtain a detailed history of the disease onset, progression, and associated symptoms. Chorea may be voluntarily suppressible (Koller and Biary 1989), but unlike tics, patients with chorea do not have premonitory urges. Compared to chorea, tic movements are usually more patterned and are repeated in a predictable and stereotypical manner.

Dystonia is a movement disorder characterized by involuntary sustained muscle contractions that produce abnormal postures or repetitive movements (Geyer and Bressman 2006). Electromyography has shown that tonic agonist and antagonist

muscle contractions occur during dystonia (Yanagisawa and Goto 1971). The etiology of dystonia is not fully understood, but structural abnormalities in the basal ganglia, cerebellum, cortex, brainstem, and thalamus, as well as neurotransmitter diseases that can affect dopaminergic dysfunction, have been suggested (Ribot et al. 2019). The most distinctive features of dystonia are sustained twisting movements, a sensory phenomenon called sensory trick (i.e., an internally generated, specific voluntary movement aimed at ameliorating the dystonia), task specificity, and directionality (e.g., alternates between quick jerking movements in one direction and slower movements in the opposite direction) (Geyer and Bressman 2006; Mink 2018). Unlike tics, dystonia is not preceded by premonitory urges.

Myoclonus is a movement disorder characterized by brief, sudden, involuntary muscle jerks. It arises from all levels of the nervous system, including the cortical and subcortical areas, brainstem, spinal cord, and peripheral areas and causes muscle contractions (positive myoclonus) or brief inhibition during sustained posture (negative myoclonus) (Mills and Mari 2015). Tics and myoclonus can be visibly indistinguishable, but some clinical features are useful to distinguish them. Myoclonus is very brief (traditionally < 200 ms on EMG), is usually non-suppressible and is not associated with a premonitory urge (Faught 2003).

11 Clinical Pearls and Key Points

- Tics are the most common movement disorder in the pediatric population.
- Most tics seem to diminish within one year.
- Tics of Tourette syndrome usually improve over time after adolescence.
- The presence of a premonitory urge, suppressibility, and suggestibility can distinguish tics from other movement disorders.
- It is important to address comorbidities such as ADHD, OCD, mood disorders, sleep disorders, and migraines.
- Treatment for tics should be considered when the tics are bothersome to patients. The first-line treatment is comprehensive behavioral therapy. If the therapy is not available or the tics are severe, pharmacological treatment should be considered.

References

- Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, et al. Sequence variants in *SLITRK1* are associated with Tourette's syndrome. *Science*. 2005;310:317–20. doi: 10.1126/science.1116502.
- Adam Y, Meinschmidt G, Gloster AT, Lieb R. Obsessive-compulsive disorder in the community: 12-month prevalence, comorbidity and impairment. *Soc Psychiatry Psychiatr Epidemiol*. 2012;47:339–49. doi: 10.1007/s00127-010-0337-5.

Albin RL, Mink JW. Recent advances in Tourette syndrome research. *Trends Neurosci.* 2006;29:175–82. doi: 10.1016/j.tins.2006.01.001.

Alderman J. Coadministration of sertraline with cisapride or pimoziide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers. *Clin Ther.* 2005;27:1050–63. doi: 10.1016/j.clinthera.2005.07.013.

Alves HL, Quagliato EM. The prevalence of tic disorders in children and adolescents in Brazil. *Arq Neuropsiquiatr.* 2014;72:942–8. doi: 10.1590/0004-282X20140174.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub. 2013.

Andrn P, Aspvall K, Fernndez de la Cruz L, Wiktor P, Romano S, Andersson E, et al. Therapist-guided and parent-guided internet-delivered behaviour therapy for paediatric Tourette's disorder: a pilot randomised controlled trial with long-term follow-up. *BMJ Open.* 2019;9:e024685. doi: 10.1136/bmjopen-2018-024685.

Aquino CC, Felcio AC, Godeiro-Junior C, Santos-Neto D, Pedroso JL, Oliveira AS, et al. Tic Disorder: An Unusual Presentation of Neurotoxoplasmosis in a Patient with AIDS. *Case Rep Neurol.* 2010;2:145–9. doi: 10.1159/000322185.

Augustine F, Singer HS. Merging the Pathophysiology and Pharmacotherapy of Tics. *Tremor Other Hyperkinet Mov (N Y).* 2019;8:595. doi: 10.7916/D8H14JTX.

Awaad Y. Tics in Tourette syndrome: new treatment options. *J Child Neurol.* 1999;14:316–9. doi: 10.1177/088307389901400508.

Awaad Y, Michon AM, Minarik S. Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. *Mov Disord.* 2005;20:714–8. doi: 10.1002/mds.20385.

Baglioni V, Coutinho E, Menassa DA, Giannoccaro MP, Jacobson L, Buttiglione M, et al. Antibodies to neuronal surface proteins in Tourette Syndrome: Lack of evidence in a European paediatric cohort. *Brain Behav Immun.* 2019;81:665–9. doi: 10.1016/j.bbi.2019.08.008.

Banaschewski T, Woerner W, Rothenberger A. Premonitory sensory phenomena and suppressibility of tics in Tourette syndrome: developmental aspects in children and adolescents. *Dev Med Child Neurol.* 2003;45:700–3. doi: 10.1017/s0012162203001294.

Bansil S, Prakash N, Kaye J, Wrigley S, Manata C, Stevens-Haas C, et al. Movement disorders after stroke in adults: a review. *Tremor Other Hyperkinet Mov (N Y).* 2012;2:tre-02-42-195-1. doi: 10.7916/D86W98TB.

Barabas G, Matthews WS, Ferrari M. Tourette's syndrome and migraine. *Arch Neurol.* 1984;41:871–2. doi: 10.1001/archneur.1984.04050190077018.

Baumgaertel C, Skripuletz T, Kronenberg J, Stangel M, Schwenkenbecher P, Sinke C, et al. Immunity in Gilles de la Tourette-Syndrome: Results From a Cerebrospinal Fluid Study. *Front Neurol.* 2019;10:732. doi: 10.3389/fneur.2019.00732.

Bernard BA, Stebbins GT, Siegel S, Schultz TM, Hays C, Morrissey MJ, et al. Determinants of quality of life in children with Gilles de la Tourette syndrome. *Mov Disord.* 2009;24:1070–3. doi: 10.1002/mds.22487.

Bharucha KJ, Sethi KD. Tardive tourettism after exposure to neuroleptic therapy. *Mov Disord*. 1995;10:791–3. doi: 10.1002/mds.870100613.

Bjerregaard VA, Schönewolf-Greulich B, Juel Rasmussen L, Desler C, Tümer Z. Mitochondrial Function in Gilles de la Tourette Syndrome Patients With and Without Intragenic IMMP2L Deletions. *Front Neurol*. 2020;11:163. doi: 10.3389/fneur.2020.00163.

Black JK, Black KJ. Software for web-based tic suppression training. *F1000Res*. 2017;6:2150. doi: 10.12688/f1000research.13460.2.

Black KJ, Black ER, Greene DJ, Schlaggar BL. Provisional Tic Disorder: What to tell parents when their child first starts ticcing. *F1000Res*. 2016;5:696. doi: 10.12688/f1000research.8428.1.

Black KJ, Kim S, Yang NY, Greene DJ. Course of tic disorders over the lifespan. 2020. Preprint doi:10.31219/osf.io/vehjr.

Bliss J, Cohen DJ, Freedman DX. Sensory experiences of Gilles de la Tourette syndrome. *Arch Gen Psychiatry*. 1980;37:1343–7. doi: 10.1001/archpsyc.1980.01780250029002.

Bloch MH, Leckman JF. Clinical course of Tourette syndrome. *J Psychosom Res*. 2009;67:497–501. doi: 10.1016/j.jpsychores.2009.09.002.

Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. *J Am Acad Child Adolesc Psychiatry*. 2009;48:884–93. doi: 10.1097/CHI.0b013e3181b26e9f.

Bloch MH, Peterson BS, Scahill L, Otko J, Katsoyich L, Zhang H, et al. Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. *Arch Pediatr Adolesc Med*. 2006;160:65–9. doi: 10.1001/archpedi.160.1.65.

Boon-yasidhi V, Kim YS, Scahill L. An open-label, prospective study of guanfacine in children with ADHD and tic disorders. *J Med Assoc Thai*. 2005;88 Suppl 8:S156–62.

Bos-Veneman NG, Olieman R, Tobiasova Z, Hoekstra PJ, Katsoyich L, Bothwell AL, et al. Altered immunoglobulin profiles in children with Tourette syndrome. *Brain Behav Immun*. 2011;25:532–8. doi: 10.1016/j.bbi.2010.12.003.

Brainstorm Consortium. Analysis of shared heritability in common disorders of the brain. *Science*. 2018;360:eaap8757. doi: 10.1126/science.aap8757.

Brand N, Geenen R, Oudenhoven M, Lindenborn B, van der Ree A, Cohen-Kettenis P, et al. Brief report: cognitive functioning in children with Tourette's syndrome with and without comorbid ADHD. *J Pediatr Psychol*. 2002;27:203–8. doi: 10.1093/jpepsy/27.2.203.

Browne HA, Hansen SN, Buxbaum JD, Gair SL, Nissen JB, Nikolajsen KH, et al. Familial clustering of tic disorders and obsessive-compulsive disorder. *JAMA Psychiatry*. 2015;72:359–66. doi: 10.1001/jamapsychiatry.2014.2656.

Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA. Risperidone versus pimozide in Tourette's disorder: a comparative

double-blind parallel-group study. *J Clin Psychiatry*. 2001;62:50–6. doi: 10.4088/jcp.v62n0111.

Bruun RD, Budman CL. Risperidone as a treatment for Tourette's syndrome. *J Clin Psychiatry*. 1996;57:29–31.

Budman CL. The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview. *Drugs*. 2014;74:1177–93. doi: 10.1007/s40265-014-0254-0.

Budman CL, Bruun RD, Park KS, Olson ME. Rage attacks in children and adolescents with Tourette's disorder: a pilot study. *J Clin Psychiatry*. 1998;59:576–80. doi: 10.4088/jcp.v59n1103.

Budman CL, Rockmore L, Stokes J, Sossin M. Clinical phenomenology of episodic rage in children with Tourette syndrome. *J Psychosom Res*. 2003;55:59–65. doi: 10.1016/s0022-3999(02)00584-6.

Burd L, Kerbeshian PJ, Barth A, Klug MG, Avery PK, Benz B. Long-term follow-up of an epidemiologically defined cohort of patients with Tourette syndrome. *J Child Neurol*. 2001;16:431–7. doi: 10.1177/088307380101600609.

Burd L, Severud R, Klug MG, Kerbeshian J. Prenatal and perinatal risk factors for Tourette disorder. *J Perinat Med*. 1999;27:295–302. doi: 10.1515/JPM.1999.042.

Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. *Neuropsychopharmacology*. 1996;14:87-96. doi: 10.1016/0893-133X(94)00129-N.

Camargo CHF, Teive HAG. Use of botulinum toxin for movement disorders. *Drugs Context*. 2019;8:212586. doi: 10.7573/dic.212586.

Canitano R, Vivanti G. Tics and Tourette syndrome in autism spectrum disorders. *Autism*. 2007;11:19–28. doi: 10.1177/1362361307070992.

Cardona F, Orefici G. Group A streptococcal infections and tic disorders in an Italian pediatric population. *J Pediatr*. 2001;138:71–5. doi: 10.1067/mpd.2001.110325.

Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Seminar on choreas. *Lancet Neurol*. 2006;5:589–602. doi: 10.1016/S1474-4422(06)70494-X.

Carter AS, O'Donnell DA, Schultz RT, Scahill L, Leckman JF, Pauls DL. Social and emotional adjustment in children affected with Gilles de la Tourette's syndrome: associations with ADHD and family functioning. *Attention Deficit Hyperactivity Disorder. J Child Psychol Psychiatry*. 2000;41:215–23.

Cavanna AE, Robertson MM, Critchley HD. Schizotypal personality traits in Gilles de la Tourette syndrome. *Acta Neurol Scand*. 2007;116:385–91. doi: 10.1111/j.1600-0404.2007.00879.x.

Channon S, Pratt P, Robertson MM. Executive function, memory, and learning in Tourette's syndrome. *Neuropsychology*. 2003;17:247–54. doi: 10.1037/0894-4105.17.2.247.

Chao TK, Hu J, Pringsheim T. Prenatal risk factors for Tourette Syndrome: a systematic review. *BMC Pregnancy Childbirth*. 2014;14:53. doi: 10.1186/1471-2393-14-53.

CHAPEL JL, BROWN N, JENKINS RL. TOURETTE'S DISEASE: SYMPTOMATIC RELIEF WITH HALOPERIDOL. *Am J Psychiatry*. 1964;121:608–10. doi: 10.1176/ajp.121.6.608.

Chappell PB, Riddle MA, Scahill L, Lynch KA, Schultz R, Arnsten A, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. *J Am Acad Child Adolesc Psychiatry*. 1995;34:1140–6. doi: 10.1097/00004583-199509000-00010.

Cheung MY, Shahed J, Jankovic J. Malignant Tourette syndrome. *Mov Disord*. 2007;22:1743–50. doi: 10.1002/mds.21599.

Church AJ, Dale RC, Lees AJ, Giovannoni G, Robertson MM. Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis. *J Neurol Neurosurg Psychiatry*. 2003;74:602–7. doi: 10.1136/jnnp.74.5.602.

Church JA, Fair DA, Dosenbach NU, Cohen AL, Miezin FM, Petersen SE, et al. Control networks in paediatric Tourette syndrome show immature and anomalous patterns of functional connectivity. *Brain*. 2009;132:225–38. doi: 10.1093/brain/awn223.

Comings DE, Comings BG. A controlled study of Tourette syndrome. I. Attention-deficit disorder, learning disorders, and school problems. *Am J Hum Genet*. 1987;41:701–41.

Conlea CA, Wellen BCM. Tic Treatment Goes Tech: A Review of TicHelper.com. *Cogn Behav Pract*. 2017;24:374–81. doi: 10.1016/j.cbpra.2017.01.003.

Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-Induced Tardive Dyskinesia: A Review and Update. *Ochsner J*. 2017;17:162–74.

Coulombe MA, Elkaim LM, Alotaibi NM, Gorman DA, Weil AG, Fallah A, et al. Deep brain stimulation for Gilles de la Tourette syndrome in children and youth: a meta-analysis with individual participant data. *J Neurosurg Pediatr*. 2018;23:236–46. doi: 10.3171/2018.7.PEDS18300.

Cox JH, Nahar A, Termine C, Agosti M, Balottin U, Seri S, et al. Social stigma and self-perception in adolescents with tourette syndrome. *Adolesc Health Med Ther*. 2019;10:75–82. doi: 10.2147/AHMT.S175765.

Cox JH, Seri S, Cavanna AE. Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders. *Pediatric Health Med Ther*. 2016;7:57–64. doi: 10.2147/PHMT.S87121.

Cubo E. Review of prevalence studies of tic disorders: methodological caveats. *Tremor Other Hyperkinet Mov (N Y)*. 2012;2:tre-02-61-349-1. doi: 10.7916/D8445K68.

Cubo E, Gabriel y Galán JM, Villaverde VA, Velasco SS, Benito VD, Macarrón JV, et al. Prevalence of tics in schoolchildren in central Spain: a population-based study. *Pediatr Neurol*. 2011;45:100–8. doi: 10.1016/j.pediatrneurol.2011.03.003.

Cunningham MW. Molecular Mimicry, Autoimmunity, and Infection: The Cross-Reactive Antigens of Group A Streptococci and their Sequelae. *Microbiol Spectr*. 2019;7:10.1128/microbiolspec.GPP3-0045-2018. doi: 10.1128/microbiolspec.GPP3-0045-2018.

Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, Derks EM, et al. Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. *PLoS Genet.* 2013;9:e1003864. doi: 10.1371/journal.pgen.1003864.

Depienne C, Ciura S, Trouillard O, Bouteiller D, Leitão E, Nava C, et al. Association of Rare Genetic Variants in Opioid Receptors with Tourette Syndrome. *Tremor Other Hyperkinet Mov (N Y).* 2019;9. doi: 10.7916/tohm.v0.693.

Dooley JM, Gordon KE, Wood EP, Camfield CS, Camfield PR. The utility of the physical examination and investigations in the pediatricneurology consultation. *Pediatr Neurol.* 2003;28:96–9. doi: 10.1016/s0887-8994(02)00494-0.

Drolet B, Rousseau G, Daleau P, Cardinal R, Simard C, Turgeon J. Pimozide (Orap) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes. *J Cardiovasc Pharmacol Ther.* 2001;6:255–60. doi: 10.1177/107424840100600306.

Du YS, Li HF, Vance A, Zhong YQ, Jiao FY, Wang HM, et al. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. *Aust N Z J Psychiatry.* 2008;42:807–13. doi: 10.1080/00048670802277222.

Eapen V, Cavanna AE, Robertson MM. Comorbidities, Social Impact, and Quality of Life in Tourette Syndrome. *Front Psychiatry.* 2016;7:97. doi: 10.3389/fpsy.2016.00097.

Eapen V, Robertson MM. Clinical correlates of tourette's disorder across cultures: a comparative study between the United Arab Emirates and the United Kingdom. *Prim Care Companion J Clin Psychiatry.* 2008;10:103–7. doi: 10.4088/pcc.v10n0203.

Eapen V, Robertson MM, Alsobrook JP 2nd, Pauls DL. Obsessive compulsive symptoms in Gilles de la Tourette syndrome and obsessive compulsive disorder: differences by diagnosis and family history. *Am J Med Genet.* 1997;74:432–8. doi: 10.1002/(sici)1096-8628(19970725)74:4<432::aid-ajmg15>3.0.co;2-j.

Eddy CM, Rickards HE, Cavanna AE. Treatment strategies for tics in Tourette syndrome. *Ther Adv Neurol Disord.* 2011a;4:25–45. doi: 10.1177/1756285610390261.

Eddy CM, Rizzo R, Gulisano M, Agodi A, Barchitta M, Calì P, et al. Quality of life in young people with Tourette syndrome: a controlled study. *J Neurol.* 2011b;258:291–301. doi: 10.1007/s00415-010-5754-6.

Edmonson MB, Farwell KR. Relationship between the clinical likelihood of group A streptococcal pharyngitis and the sensitivity of a rapid antigen-detection test in a pediatric practice. *Pediatrics.* 2005;115:280–5. doi: 10.1542/peds.2004-0907.

Ercan-Sencicek AG, Stillman AA, Ghosh AK, Bilguvar K, O'Roak BJ, Mason CE, et al. L-histidine decarboxylase and Tourette's syndrome. *N Engl J Med.* 2010;362:1901–8. doi: 10.1056/NEJMoa0907006.

Factor SA, Molho ES. Adult-onset tics associated with peripheral injury. *Mov Disord.* 1997;12:1052–5. doi: 10.1002/mds.870120634.

Fahn S, Jankovic J, Hallett M. Tics and Tourette syndrome. In: Principles and practice of movement disorders E-book. Elsevier Health Sciences; 2011. p. 350–79.

Faught E. Clinical presentations and phenomenology of myoclonus. *Epilepsia*. 2003;44 Suppl 11:7–12. doi: 10.1046/j.1528-1157.44.s11.3.x.

Fernández-Jaén A, Fernández-Mayoralas DM, Muñoz-Jareño N, Calleja-Pérez B. An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome. *Eur J Paediatr Neurol*. 2009;13:541–5. doi: 10.1016/j.ejpn.2008.12.006.

Fernández de la Cruz L, Rydell M, Runeson B, Brander G, Rück C, D'Onofrio BM, et al. Suicide in Tourette's and Chronic Tic Disorders. *Biol Psychiatry*. 2017;82:111–8. doi: 10.1016/j.biopsych.2016.08.023.

Ferrão YA, Miguel E, Stein DJ. Tourette's syndrome, trichotillomania, and obsessive-compulsive disorder: how closely are they related? *Psychiatry Res*. 2009;170:32–42. doi: 10.1016/j.psychres.2008.06.008.

Flockhart DA, Drici MD, Kerbusch T, Soukhova N, Richard E, Pearle PL, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. *J Clin Psychopharmacol*. 2000;20:317–24. doi: 10.1097/00004714-200006000-00005.

Frankovich J, Swedo S, Murphy T, Dale RC, Agalliu D, Williams K, et al. Clinical management of pediatric acute-onset neuropsychiatric syndrome: Part II—use of immunomodulatory therapies. *J Child Adolesc Psychopharmacol*. 2017;27:574–93. doi: abs/10.1089/cap.2016.0148.

Freeman RD, Fast DK, Burd L, Kerbeshian J, Robertson MM, Sandor P. An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. *Dev Med Child Neurol*. 2000;42:436–47. doi: 10.1017/s0012162200000839.

Freeman RD, Soltanifar A, Baer S. Stereotypic movement disorder: easily missed. *Dev Med Child Neurol*. 2010;52:733–8. doi: 10.1111/j.1469-8749.2010.03627.x.

Fründt O, Woods D, Ganos C. Behavioral therapy for Tourette syndrome and chronic tic disorders. *Neurol Clin Pract*. 2017;7:148–56. doi: 10.1212/CPJ.0000000000000348.

Gabbay V, Coffey BJ, Babb JS, Meyer L, Wachtel C, Anam S, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcus: comparison of diagnosis and treatment in the community and at a specialty clinic. *Pediatrics*. 2008;122:273–8. doi: 10.1542/peds.2007-1307.

Gadow KD, Nolan EE, Sprafkin J, Schwartz J. Tics and psychiatric comorbidity in children and adolescents. *Dev Med Child Neurol*. 2002;44:330-8.

Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. *J Am Acad Child Adolesc Psychiatry*. 2002;41:330–6. doi: 10.1097/00004583-200203000-00013.

Ganos C, Bongert J, Asmuss L, Martino D, Haggard P, Münchau A. The somatotopy of tic inhibition: Where and how much? *Mov Disord*. 2015;30:1184–9. doi: 10.1002/mds.26188.

George SK, Jiao Y, Bishop CE, Lu B. Mitochondrial peptidase IMMP2L mutation causes early onset of age-associated disorders and impairs adult stem cell self-renewal. *Aging Cell*. 2011;10:584–94. doi: 10.1111/j.1474-9726.2011.00686.x.

Georgitsi M, Willsey AJ, Mathews CA, State M, Scharf JM, Paschou P. The Genetic Etiology of Tourette Syndrome: Large-Scale Collaborative Efforts on the Precipice of Discovery. *Front Neurosci*. 2016;10:351. doi: 10.3389/fnins.2016.00351.

Gerber MA, Randolph MF, Mayo DR. The group A streptococcal carrier state. A reexamination. *Am J Dis Child*. 1988;142:562–5. doi: 10.1001/archpedi.1988.02150050100043.

Geyer HL, Bressman SB. The diagnosis of dystonia. *Lancet Neurol*. 2006;5:780–90. doi: 10.1016/S1474-4422(06)70547-6.

Ghosh D, Rajan PV, Das D, Datta P, Rothner AD, Erenberg G. Headache in children with Tourette syndrome. *J Pediatr*. 2012;161:303–7. doi: 10.1016/j.jpeds.2012.01.072.

Ghosh D, Rajan PV, Das D, Datta P, Rothner AD, Erenberg G. Sleep disorders in children with Tourette syndrome. *Pediatr Neurol*. 2014;51:31–5. doi: 10.1016/j.pediatrneurol.2014.03.017.

Gilbert DL. Acute and chronic chorea in childhood. *Semin Pediatr Neurol*. 2009;16:71–6. doi: 10.1016/j.spen.2009.03.009.

Gilbert DL. Inflammation in Tic Disorders and Obsessive-Compulsive Disorder: Are PANS and PANDAS a Path Forward? *J Child Neurol*. 2019;34:598–611. doi: 10.1177/0883073819848635.

Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. *J Am Acad Child Adolesc Psychiatry*. 2004;43:206–14. doi: 10.1097/00004583-200402000-00017.

Gilbert DL, Mink JW, Singer HS. A Pediatric Neurology Perspective on Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection and Pediatric Acute-Onset Neuropsychiatric Syndrome. *J Pediatr*. 2018a;199:243–51. doi: 10.1016/j.jpeds.2018.04.035.

Gilbert DL, Murphy TK, Jankovic J, Budman CL, Black KJ, Kurlan RM, et al. Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. *Mov Disord*. 2018b;33:1272–80. doi: 10.1002/mds.27457.

Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. *Br J Psychiatry*. 1990;157:585–92. doi: 10.1192/bjp.157.4.585.

Goetz CG, Leurgans S, Chmura TA. Home alone: methods to maximize tic expression for objective videotape assessments in Gilles de la Tourette syndrome. *Mov Disord*. 2001;16:693–7. doi: 10.1002/mds.1159.

Goetz CG, Tanner CM, Stebbins GT, Leipzig G, Carr WC. Adult tics in Gilles de la Tourette's syndrome: description and risk factors. *Neurology*. 1992;42:784–8. doi: 10.1212/wnl.42.4.784.

Goldenberg JN, Brown SB, Weiner WJ. Coprolalia in younger patients with Gilles de la Tourette syndrome. *Mov Disord*. 1994;9:622–5. doi: 10.1002/mds.870090607.

Groth C, Mol Debes N, Rask CU, Lange T, Skov L. Course of Tourette Syndrome and Comorbidities in a Large Prospective Clinical Study. *J Am Acad Child Adolesc Psychiatry*. 2017;56:304–12. doi: 10.1016/j.jaac.2017.01.010.

Gulisano M, Cali PV, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. *Neurol Sci*. 2011;32:1213–7. doi: 10.1007/s10072-011-0678-1.

Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: A statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. *Circulation*. 1999;99:979–82. doi: 10.1161/01.cir.99.7.979.

Hedderick EF, Morris CM, Singer HS. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. *Pediatr Neurol*. 2009;40:420–5. doi: 10.1016/j.pediatrneurol.2008.12.014.

Helm CE, Blackwood RA. Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS): Experience at a Tertiary Referral Center. *Tremor Other Hyperkinet Mov (N Y)*. 2015;5:270. doi: 10.7916/D8348JCX.

Hesselmark E, Bejerot S. Biomarkers for diagnosis of Pediatric Acute Neuropsychiatric Syndrome (PANS) - Sensitivity and specificity of the Cunningham Panel. *J Neuroimmunol*. 2017;312:31–7. doi: 10.1016/j.jneuroim.2017.09.002.

Himle MB, Woods DW, Piacentini JC, Walkup JT. Brief review of habit reversal training for Tourette syndrome. *J Child Neurol*. 2006;21:719–25. doi: 10.1177/08830738060210080101.

Hirschtritt ME, Lee PC, Pauls DL, Dion Y, Grados MA, Illmann C, et al. Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. *JAMA Psychiatry*. 2015;72:325–33. doi: 10.1001/jamapsychiatry.2014.2650.

Hirschtritt ME, Darrow SM, Illmann C, Osiecki L, Grados M, Sandor P, et al. Genetic and phenotypic overlap of specific obsessive-compulsive and attention-deficit/hyperactive subtypes with Tourette syndrome. *Psychol Med*. 2018;48:279–93. doi: 10.1017/S0033291717001672.

Hoekstra PJ, Minderaa RB, Kallenberg CG. Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study. *J Clin Psychiatry*. 2004;65:537–42. doi: 10.4088/jcp.v65n0413.

Holzer JC, Goodman WK, McDougle CJ, Baer L, Boyarsky BK, Leckman JF, et al. Obsessive-compulsive disorder with and without a chronic tic disorder. A

comparison of symptoms in 70 patients. *Br J Psychiatry*. 1994;164:469–73. doi: 10.1192/bjp.164.4.469.

Hoogduin, K., Verdellen, C, Cath, D. Exposure and response prevention in the treatment of Gilles de la Tourette's syndrome: four case studies. *Clin. Psychol. Psychother.* 1997;4:125–35. doi.org/10.1002/(SICI)1099-0879(199706)4:2<125::AID-CPP125>3.0.CO;2-Z

Horesh N, Zimmerman S, Steinberg T, Yagan H, Apter A. Is onset of Tourette syndrome influenced by life events? *J Neural Transm (Vienna)*. 2008;115:787–93. doi: 10.1007/s00702-007-0014-3.

Hornsey H, Banerjee S, Zeitlin H, Robertson M. The prevalence of Tourette syndrome in 13-14-year-olds in mainstream schools. *J Child Psychol Psychiatry*. 2001;42:1035–9. doi: 10.1111/1469-7610.00802.

Howell S, Yarovova E, Khwanda A, Rosen SD. Cardiovascular effects of psychotic illnesses and antipsychotic therapy. *Heart*. 2019;105:1852–9. doi: 10.1136/heartjnl-2017-312107.

Huang AY, Yu D, Davis LK, Sul JH, Tsetsos F, Ramensky V, et al. Rare Copy Number Variants in NRXN1 and CNTN6 Increase Risk for Tourette Syndrome. *Neuron*. 2017;94:1101–11. doi: 10.1016/j.neuron.2017.06.010.

Huys D, Hardenacke K, Poppe P, Bartsch C, Baskin B, Kuhn J. Update on the role of antipsychotics in the treatment of Tourette syndrome. *Neuropsychiatr Dis Treat*. 2012;8:95–104. doi: 10.2147/NDT.S12990.

Hyde TM, Aaronson BA, Randolph C, Rickler KC, Weinberger DR. Relationship of birth weight to the phenotypic expression of Gilles de la Tourette's syndrome in monozygotic twins. *Neurology*. 1992;42:652–8. doi: 10.1212/wnl.42.3.652.

Jackson GM, Draper A, Dyke K, Pépés SE, Jackson SR. Inhibition, Disinhibition, and the Control of Action in Tourette Syndrome. *Trends Cogn Sci*. 2015;19:655–65. doi: 10.1016/j.tics.2015.08.006.

Jankovic J. Tourette syndrome. Phenomenology and classification of tics. *Neurol Clin*. 1997;15:267–75. doi: 10.1016/s0733-8619(05)70311-x.

Jankovic J. Tourette's syndrome. *N Engl J Med*. 2001;345:1184–92. doi: 10.1056/NEJMra010032.

Jankovic J. Botulinum toxin in clinical practice. *J Neurol Neurosurg Psychiatry*. 2004;75:951–7. doi: 10.1136/jnnp.2003.034702.

Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. *Expert Opin Pharmacother*. 2016;17:2461–70. doi: 10.1080/14656566.2016.1258063.

Jankovic J. Treatment of tics associated with Tourette syndrome. *J Neural Transm (Vienna)*. 2020;127:843–50. doi: 10.1007/s00702-019-02105-w.

Jankovic J, Ashizawa T. Tourettism associated with Huntington's disease. *Mov Disord*. 1995;10:103–5. doi: 10.1002/mds.870100116.

Jankovic J, Gelineau-Kattner R, Davidson A. Tourette's syndrome in adults. *Mov Disord*. 2010a;25:2171–5. doi: 10.1002/mds.23199.

Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. *J Neurol Neurosurg Psychiatry*. 2010b;81:70–3. doi: 10.1136/jnnp.2009.185348.

Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. *Mov Disord*. 2011;26:1149–56. doi: 10.1002/mds.23618.

Jankovic J, Kwak C, Frankoff R. Tourette's syndrome and the law. *J Neuropsychiatry Clin Neurosci*. 2006;18:86–95. doi: 10.1176/jnp.18.1.86.

Jankovic J, Rohaidy H. Motor, behavioral and pharmacologic findings in Tourette's syndrome. *Can J Neurol Sci*. 1987;14(3 Suppl):541–6. doi: 10.1017/s0317167100038087.

Jenner P, Pratt JA, Marsden CD. Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT. *Adv Neurol*. 1986;43:629–43.

Johnco C, McGuire JF, McBride NM, Murphy TK, Lewin AB, Storch EA. Suicidal ideation in youth with tic disorders. *J Affect Disord*. 2016;200:204–11. doi: 10.1016/j.jad.2016.04.027.

Johnson KA, Fletcher PT, Servello D, Bona A, Porta M, Ostrem JL, et al. Image-based analysis and long-term clinical outcomes of deep brain stimulation for Tourette syndrome: a multisite study. *J Neurol Neurosurg Psychiatry*. 2019;90:1078–90. doi: 10.1136/jnnp-2019-320379.

Johnson DR, Kurlan R, Leckman J, Kaplan EL. The human immune response to streptococcal extracellular antigens: clinical, diagnostic, and potential pathogenic implications. *Clin Infect Dis*. 2010;50:481–90. doi: 10.1086/650167.

Kaim B. A case of Gilles de la Tourette's syndrome treated with clonazepam. *Brain Res Bull*. 1983;11:213–4. doi: 10.1016/0361-9230(83)90194-6.

Karaş H, Güdük M, Saatcioğlu Ö. Withdrawal-Emergent Dyskinesia and Supersensitivity Psychosis Due to Olanzapine Use. *Noro Psikiyatr Ars*. 2016;53:178–80. doi: 10.5152/npa.2015.10122.

Katherine M. Stereotypic Movement Disorders. *Semin Pediatr Neurol*. 2018;25:19–24. doi: 10.1016/j.spen.2017.12.004.

Kaufmann C, Agalawatta N, Malhi GS. Catatonia: Stereotypies, mannerisms and perseverations. *Aust N Z J Psychiatry*. 2018;52:391–3. doi: 10.1177/0004867418765669.

Kaur N, Kumar P, Jamwal S, Deshmukh R, Gauttam V. Tetrabenazine: Spotlight on Drug Review. *Ann Neurosci*. 2016;23:176–85. doi: 10.1159/000449184.

Kawikova I, Leckman JF, Kronig H, Katsoyich L, Bessen DE, Ghebremichael M, et al. Decreased numbers of regulatory T cells suggest impaired immune tolerance in children with tourette syndrome: a preliminary study. *Biol Psychiatry*. 2007;61:273–8. doi: 10.1016/j.biopsych.2006.06.012.

Keck PE Jr, McElroy SL, Arnold LM. Ziprasidone: a new atypical antipsychotic. *Expert Opin Pharmacother*. 2001;2:1033–42. doi: 10.1517/14656566.2.6.1033.

Kenney CJ, Hunter CB, Mejia NI, Jankovic J. Tetrabenazine in the treatment of Tourette syndrome. *J Ped Neurol*. 2007;5:9–13.

Khalifa N, von Knorring AL. Prevalence of tic disorders and Tourette syndrome in a Swedish school population. *Dev Med Child Neurol*. 2003;45:315–9. doi: 10.1017/s0012162203000598.

Khalifa N, von Knorring AL. Tourette syndrome and other tic disorders in a total population of children: clinical assessment and background. *Acta Paediatr*. 2005;94:1608–14. doi: 10.1111/j.1651-2227.2005.tb01837.x.

Kiessling LS, Marcotte AC, Culpepper L. Antineuronal antibodies in movement disorders. *Pediatrics*. 1993;92:39–43.

Kim S, Greene DJ, Bihun EC, Koller JM, Hampton JM, Acevedo H, et al. Provisional Tic Disorder is not so transient. *Sci Rep*. 2019;9:3951. doi: 10.1038/s41598-019-40133-4.

Kirov R, Kinkelbur J, Banaschewski T, Rothenberger A. Sleep patterns in children with attention-deficit/hyperactivity disorder, tic disorder, and comorbidity. *J Child Psychol Psychiatry*. 2007;48:561–70. doi: 10.1111/j.1469-7610.2007.01729.x.

Klawans HL, Barr A. Recurrence of childhood multiple tic in late adult life. *Arch Neurol*. 1985;42:1079–80. doi: 10.1001/archneur.1985.04060100061023.

Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T. Prevalence of tic disorders: a systematic review and meta-analysis. *Pediatr Neurol*. 2012;47:77–90. doi: 10.1016/j.pediatrneurol.2012.05.002.

Koller WC, Biary NM. Volitional control of involuntary movements. *Mov Disord*. 1989;4:153–6. doi: 10.1002/mds.870040207.

Kollins SH, Jain R, Brams M, Segal S, Findling RL, Wigal SB, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. *Pediatrics*. 2011;127:e1406–13. doi: 10.1542/peds.2010-1260.

Kompoliti K, Fan W, Leurgans S. Complementary and alternative medicine use in Gilles de la Tourette syndrome. *Mov Disord*. 2009;24:2015–9. doi: 10.1002/mds.22724.

Kondo K, Kabasawa T. Improvement in Gilles de la Tourette syndrome after corticosteroid therapy. *Ann Neurol*. 1978;4:387. doi: 10.1002/ana.410040423.

Kovacs N, Herold R, Janszky J, Komoly S, Nagy F. Tics status: a movement disorder emergency: observations. *J Neurol*. 2011;258:143–5. doi: 10.1007/s00415-010-5680-7.

Krauss JK, Jankovic J. Severe motor tics causing cervical myelopathy in Tourette's syndrome. *Mov Disord*. 1996;11:563–6. doi: 10.1002/mds.870110512.

Kumar A, Duda L, Mainali G, Asghar S, Byler D. A Comprehensive Review of Tourette Syndrome and Complementary Alternative Medicine. *Curr Dev Disord Rep*. 2018;5:95–100. doi: 10.1007/s40474-018-0137-2.

Kumar R, Lang AE. Tourette syndrome. Secondary tic disorders. *Neurol Clin*. 1997;15:309–31. doi: 10.1016/s0733-8619(05)70315-7.

Kuo SH, Jimenez-Shahed J. Topiramate in treatment of tourette syndrome. *Clin Neuropharmacol*. 2010;33:32–4. doi: 10.1097/WNF.0b013e3181c295c1.

Kurlan R. Methylphenidate to treat ADHD is not contraindicated in children with tics. *Mov Disord.* 2002;17:5–6. doi: 10.1002/mds.10094.

Kurlan R, Behr J, Medved L, Shoulson I, Pauls D, Kidd JR, et al. Familial Tourette's syndrome: report of a large pedigree and potential for linkage analysis. *Neurology.* 1986;36:772–6. doi: 10.1212/wnl.36.6.772.

Kurlan R, Behr J, Medved L, Shoulson I, Pauls D, Kidd KK. Severity of Tourette's syndrome in one large kindred. Implication for determination of disease prevalence rate. *Arch Neurol.* 1987;44:268–9. doi: 10.1001/archneur.1987.00520150024013.

Kurlan R, McDermott MP, Deeley C, Como PG, Brower C, Eapen S, et al. Prevalence of tics in schoolchildren and association with placement in special education. *Neurology.* 2001;57:1383–8. doi: 10.1212/wnl.57.8.1383.

Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. *Mov Disord.* 2003a;18:1530–3. doi: 10.1002/mds.10618.

Kwak C, Vuong KD, Jankovic J. Migraine headache in patients with Tourette syndrome. *Arch Neurol.* 2003b;60:1595–8. doi: 10.1001/archneur.60.11.1595.

Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. *Arch Neurol.* 2000;57:1190–3. doi: 10.1001/archneur.57.8.1190.

Lamothe H, Baleyte JM, Mallet L, Pelissolo A. Trichotillomania is more related to Tourette disorder than to obsessive-compulsive disorder. *Braz J Psychiatry.* 2020;42:87–104. doi: 10.1590/1516-4446-2019-0471.

Lavoie ME, O'Connor K. Toward a Multifactorial Conception of the Gilles de la Tourette Syndrome and Persistent Chronic Tic Disorder. *Brain Sci.* 2017;7:61. doi: 10.3390/brainsci7060061.

Law SF, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? *J Am Acad Child Adolesc Psychiatry.* 1999;38:944–51. doi: 10.1097/00004583-199908000-00009.

Lawson-Yuen A, Saldivar JS, Sommer S, Picker J. Familial deletion within NLGN4 associated with autism and Tourette syndrome. *Eur J Hum Genet.* 2008;16:614–8. doi: 10.1038/sj.ejhg.5202006.

Leckman JF. Tourette's syndrome. *Lancet.* 2002;360:1577–86. doi: 10.1016/S0140-6736(02)11526-1.

Leckman JF, Dolnansky ES, Hardin MT, Clubb M, Walkup JT, Stevenson J, et al. Perinatal factors in the expression of Tourette's syndrome: an exploratory study. *J Am Acad Child Adolesc Psychiatry.* 1990;29:220–6. doi: 10.1097/00004583-199003000-00010.

Leckman JF, Grice DE, Barr LC, de Vries AL, Martin C, Cohen DJ, McDougle CJ, Goodman WK, Rasmussen SA. Tic-related vs. non-tic-related obsessive compulsive disorder. *Anxiety.* 1994a;1:208–15.

Leckman JF, Katsoyich L, Kawikova I, Lin H, Zhang H, Krönig H, et al. Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette's syndrome. *Biol Psychiatry.* 2005;57:667–73. doi: 10.1016/j.biopsych.2004.12.004.

Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. *J Am Acad Child Adolesc Psychiatry*. 1989;28:566–73. doi: 10.1097/00004583-198907000-00015.

Leckman JF, Walker DE, Cohen DJ. Premonitory urges in Tourette's syndrome. *Am J Psychiatry*. 1993;150:98–102. doi: 10.1176/ajp.150.1.98.

Leckman JF, Walker DE, Goodman WK, Pauls DL, Cohen DJ. "Just right" perceptions associated with compulsive behavior in Tourette's syndrome. *Am J Psychiatry*. 1994b;151:675–80. doi: 10.1176/ajp.151.5.675.

Leckman JF, Zhang H, Vitale A, Lahnin F, Lynch K, Bondi C, et al. Course of tic severity in Tourette syndrome: the first two decades. *Pediatrics*. 1998;102:14–9. doi: 10.1542/peds.102.1.14.

Lee WT, Huang HL, Wong LC, Weng WC, Vasylenko T, Jong YJ, et al. Tourette Syndrome as an Independent Risk Factor for Subsequent Sleep Disorders in Children: A Nationwide Population-Based Case-Control Study. *Sleep*. 2017;40. doi: 10.1093/sleep/zsw072.

Leivonen S, Scharf JM, Mathews CA, Chudal R, Gyllenberg D, Sucksdorff D, et al. Parental Psychopathology and Tourette Syndrome/Chronic Tic Disorder in Offspring: A Nationwide Case-Control Study. *J Am Acad Child Adolesc Psychiatry*. 2017;56:297–303. doi: 10.1016/j.jaac.2017.01.009.

Lieberman JA 3rd. Metabolic changes associated with antipsychotic use. *Prim Care Companion J Clin Psychiatry*. 2004;6(Suppl 2):8–13.

Liu S, Tian M, He F, Li J, Xie H, Liu W, et al. Mutations in *ASH1L* confer susceptibility to Tourette syndrome. *Mol Psychiatry*. 2020;25:476–490. doi: 10.1038/s41380-019-0560-8.

Liu S, Yu X, Xu Q, Cui J, Yi M, Zhang X, et al. Support of positive association in family-based genetic analysis between *COL27A1* and Tourette syndrome. *Sci Rep*. 2015;5:12687. doi: 10.1038/srep12687.

Lombroso PJ, Scahill L. Tourette syndrome and obsessive-compulsive disorder. *Brain Dev*. 2008;30:231–7. doi: 10.1016/j.braindev.2007.09.001.

Lougee L, Perlmutter SJ, Nicolson R, Garvey MA, Swedo SE. Psychiatric disorders in first-degree relatives of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). *J Am Acad Child Adolesc Psychiatry*. 2000;39:1120–6. doi: 10.1097/00004583-200009000-00011.

Lowe TL, Capriotti MR, McBurnett K. Long-Term Follow-up of Patients with Tourette's Syndrome. *Mov Disord Clin Pract*. 2018;6:40–5. doi: 10.1002/mdc3.12696.

Lyon GJ, Samar SM, Conelea C, Trujillo MR, Lipinski CM, Bauer CC, et al. Testing tic suppression: comparing the effects of dexamethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder. *J Child Adolesc Psychopharmacol*. 2010;20:283–9. doi: 10.1089/cap.2010.0032.

Lyseng-Williamson KA, Yang LP. Topiramate: a review of its use in the treatment of epilepsy. *Drugs*. 2007;67:2231–56. doi: 10.2165/00003495-200767150-00008.

Marras C, Andrews D, Sime E, Lang AE. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. *Neurology*. 2001;56:605–10. doi: 10.1212/wnl.56.5.605.

Martinez-Ramirez D, Jimenez-Shahed J, Leckman JF, Porta M, Servello D, Meng FG, et al. Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry. *JAMA Neurol*. 2018;75:353–9. doi: 10.1001/jamaneurol.2017.4317.

Martino D, Church AJ, Defazio G, Dale RC, Quinn NP, Robertson MM, et al. Soluble adhesion molecules in Gilles de la Tourette's syndrome. *J Neurol Sci*. 2005;234:79–85. doi: 10.1016/j.jns.2005.03.032.

Martino D, Hedderly T. Tics and stereotypies: A comparative clinical review. *Parkinsonism Relat Disord*. 2019;59:117–24. doi: 10.1016/j.parkreldis.2019.02.005.

Martino D, Pringsheim TM, Cavanna AE, Colosimo C, Hartmann A, Leckman JF, et al. Systematic review of severity scales and screening instruments for tics: Critique and recommendations. *Mov Disord*. 2017;32:467–73. doi: 10.1002/mds.26891.

Martino D, Zis P, Buttiglione M. The role of immune mechanisms in Tourette syndrome. *Brain Res*. 2015;1617:126–43. doi: 10.1016/j.brainres.2014.04.027.

Marwitz L, Pringsheim T. Clinical Utility of Screening for Anxiety and Depression in Children with Tourette Syndrome. *J Can Acad Child Adolesc Psychiatry*. 2018;27:15–21.

Mason A, Banerjee S, Eapen V, Zeitlin H, Robertson MM. The prevalence of Tourette syndrome in a mainstream school population. *Dev Med Child Neurol*. 1998;40:292–6.

Mataix-Cols D, Isomura K, Pérez-Vigil A, Chang Z, Rück C, Larsson KJ, et al. Familial Risks of Tourette Syndrome and Chronic Tic Disorders. A Population-Based Cohort Study. *JAMA Psychiatry*. 2015;72:787–93. doi: 10.1001/jamapsychiatry.2015.0627.

Matarazzo EB. Tourette's Syndrome Treated with ACTH and Prednisone: Report of Two Cases. *J Child Adolesc Psychopharmacol*. 1992;2:215–26. doi: 10.1089/cap.1992.2.215.

Mathews CA, Grados MA. Familiality of Tourette syndrome, obsessive-compulsive disorder, and attention-deficit/hyperactivity disorder: heritability analysis in a large sib-pair sample. *J Am Acad Child Adolesc Psychiatry*. 2011;50:46–54. doi: 10.1016/j.jaac.2010.10.004.

Mathews CA, Scharf JM, Miller LL, Macdonald-Wallis C, Lawlor DA, Ben-Shlomo Y. Association between pre- and perinatal exposures and Tourette syndrome or chronic tic disorder in the ALSPAC cohort. *Br J Psychiatry*. 2014;204:40–5. doi: 10.1192/bjp.bp.112.125468.

Mathews CA, Waller J, Glidden D, Lowe TL, Herrera LD, Budman CL, et al. Self injurious behaviour in Tourette syndrome: correlates with impulsivity and impulse control. *J Neurol Neurosurg Psychiatry*. 2004;75:1149–55. doi: 10.1136/jnnp.2003.020693.

McCracken JT, Suddath R, Chang S, Thakur S, Piacentini J. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. *J Child Adolesc Psychopharmacol*. 2008;18:501–8. doi: 10.1089/cap.2007.135.

Meier SM, Dalsgaard S, Mortensen PB, Leckman JF, Plessen KJ. Mortality risk in a nationwide cohort of individuals with tic disorders and with tourette syndrome. *Mov Disord*. 2017;32:605–9. doi: 10.1002/mds.26939.

Mejia NI, Jankovic J. Secondary tics and tourettism. *Braz J Psychiatry*. 2005;27:11–7. doi: 10.1590/s1516-44462005000100006.

Merikangas JR, Merikangas KR, Kopp U, Hanin I. Blood choline and response to clonazepam and haloperidol in Tourette's syndrome. *Acta Psychiatr Scand*. 1985;72:395–9. doi: 10.1111/j.1600-0447.1985.tb02628.x.

Mills K, Mari Z. An update and review of the treatment of myoclonus. *Curr Neurol Neurosci Rep*. 2015;15:512. doi: 10.1007/s11910-014-0512-2.

Ming X, Mulvey M, Mohanty S, Patel V. Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders. *Adolesc Health Med Ther*. 2011;2:105–12. doi: 10.2147/AHMT.S15672.

Mink JW. The Basal Ganglia and involuntary movements: impaired inhibition of competing motor patterns. *Arch Neurol*. 2003;60:1365–8. doi: 10.1001/archneur.60.10.1365.

Mink JW. Basal ganglia mechanisms in action selection, plasticity, and dystonia. *Eur J Paediatr Neurol*. 2018;22:225–9. doi: 10.1016/j.ejpn.2018.01.005.

Mol Debes NM, Hjalgrim H, Skov L. Validation of the presence of comorbidities in a Danish clinical cohort of children with Tourette syndrome. *J Child Neurol*. 2008;23:1017–27. doi: 10.1177/0883073808316370.

Morshed SA, Parveen S, Leckman JF, Mercadante MT, Bittencourt Kiss MH, Miguel EC, et al. Antibodies against neural, nuclear, cytoskeletal, and streptococcal epitopes in children and adults with Tourette's syndrome, Sydenham's chorea, and autoimmune disorders. *Biol Psychiatry*. 2001;50:566–77. doi: 10.1016/s0006-3223(01)01096-4.

Müller-Vahl KR, Sambrani T, Jakubovski E. Tic disorders revisited: introduction of the term "tic spectrum disorders". *Eur Child Adolesc Psychiatry*. 2019;28:1129–35. doi: 10.1007/s00787-018-01272-7.

Mulligan HF, Anderson TJ, Jones RD, Williams MJ, Donaldson IM. Tics and developmental stuttering. *Parkinsonism Relat Disord*. 2003;9:281–9. doi: 10.1016/s1353-8020(03)00002-6.

Murphy TK, Fernandez TV, Coffey BJ, Rahman O, Gavaletz A, Hanks CE, et al. Extended-Release Guanfacine Does Not Show a Large Effect on Tic Severity

in Children with Chronic Tic Disorders. *J Child Adolesc Psychopharmacol*. 2017;27:762–70. doi: 10.1089/cap.2017.0024.

Nielsen AN, Gratton C, Church JA, Dosenbach NUF, Black KJ, Petersen SE, et al. Atypical Functional Connectivity in Tourette Syndrome Differs Between Children and Adults. *Biol Psychiatry*. 2020;87:164–73. doi: 10.1016/j.biopsych.2019.06.021.

Oakley C, Mahone EM, Morris-Berry C, Kline T, Singer HS. Primary complex motor stereotypies in older children and adolescents: clinical features and longitudinal follow-up. *Pediatr Neurol*. 2015;52:398–403. doi: 10.1016/j.pediatrneurol.2014.11.002.

Palma E, Ragozzino D, Di Angelantonio S, Mascia A, Maiolino F, Manfredi M, et al. The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation. *Epilepsia*. 2007;48:1842–9. doi: 10.1111/j.1528-1167.2007.01131.x.

Palumbo D, Kurlan R. Complex obsessive compulsive and impulsive symptoms in Tourette's syndrome. *Neuropsychiatr Dis Treat*. 2007;3:687–93.

Pappert EJ, Goetz CG, Louis ED, Blasucci L, Leurgans S. Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome. *Neurology*. 2003;61:936–40. doi: 10.1212/01.wnl.0000086370.10186.7c.

Pascual-Leone A, Dhuna A. Cocaine-associated multifocal tics. *Neurology*. 1990;40:999–1000. doi: 10.1212/wnl.40.6.999.

Patel C, Cooper-Charles L, McMullan DJ, Walker JM, Davison V, Morton J. Translocation breakpoint at 7q31 associated with tics: further evidence for IMMP2L as a candidate gene for Tourette syndrome. *Eur J Hum Genet*. 2011;19:634–9. doi: 10.1038/ejhg.2010.238.

Pauls DL, Fernandez TV, Mathews CA, State MW, Scharf JM. The Inheritance of Tourette Disorder: A review. *J Obsessive Compuls Relat Disord*. 2014;3:380–5. doi: 10.1016/j.jocrd.2014.06.003.

Pauls DL, Leckman JF. The inheritance of Gilles de la Tourette's syndrome and associated behaviors. Evidence for autosomal dominant transmission. *N Engl J Med*. 1986;315:993–7. doi: 10.1056/NEJM198610163151604.

Pérez-Vigil A, Fernández de la Cruz L, Brander G, Isomura K, Jangmo A, Kuja-Halkola R, et al. Association of Tourette Syndrome and Chronic Tic Disorders With Objective Indicators of Educational Attainment: A Population-Based Sibling Comparison Study. *JAMA Neurol*. 2018;75:1098–105. doi: 10.1001/jamaneurol.2018.1194.

Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. *Lancet*. 1999;354:1153–8. doi: 10.1016/S0140-6736(98)12297-3.

Petek E, Windpassinger C, Vincent JB, Cheung J, Boright AP, Scherer SW, et al. Disruption of a novel gene (IMMP2L) by a breakpoint in 7q31 associated with Tourette syndrome. *Am J Hum Genet*. 2001;68:848–58. doi: 10.1086/319523.

Peterson BS, Thomas P, Kane MJ, Scahill L, Zhang H, Bronen R, et al. Basal Ganglia volumes in patients with Gilles de la Tourette syndrome. *Arch Gen Psychiatry*. 2003;60:415–24. doi: 10.1001/archpsyc.60.4.415.

Piacentini J, Woods DW, Scahill L, Wilhelm S, Peterson AL, Chang S, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. *JAMA*. 2010;303:1929–37. doi: 10.1001/jama.2010.607.

Piedad JC, Cavanna AE. Depression in Tourette syndrome: A controlled and comparison study. *J Neurol Sci*. 2016;364:128–32. doi: 10.1016/j.jns.2016.03.030.

Porta M, Maggioni G, Ottaviani F, Schindler A. Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. *Neurol Sci*. 2004;24:420–3. doi: 10.1007/s10072-003-0201-4.

Porta M, Sassi M, Cavallazzi M, Fornari M, Brambilla A, Servello D. Tourette's syndrome and role of tetrabenazine: review and personal experience. *Clin Drug Investig*. 2008;28:443–59. doi: 10.2165/00044011-200828070-00006.

Price RA, Kidd KK, Cohen DJ, Pauls DL, Leckman JF. A twin study of Tourette syndrome. *Arch Gen Psychiatry*. 1985;42:815–20. doi: 10.1001/archpsyc.1985.01790310077011.

Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billingshurst L, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. *Can J Psychiatry*. 2012;57:133–43. doi: 10.1177/070674371205700302.

Pringsheim T, Okun MS, Müller-Vahl K, Martino D, Jankovic J, Cavanna AE, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. *Neurology*. 2019;92:896–906. doi: 10.1212/WNL.00000000000007466.

Proenca CC, Gao KP, Shmelkov SV, Rafii S, Lee FS. Slitrks as emerging candidate genes involved in neuropsychiatric disorders. *Trends Neurosci*. 2011;34:143–53. doi: 10.1016/j.tins.2011.01.001.

Qasaymeh MM, Mink JW. New treatments for tic disorders. *Curr Treat Options Neurol*. 2006;8:465–73. doi: 10.1007/s11940-006-0036-4.

Quezada J, Coffman KA. Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome. *CNS Drugs*. 2018;32:33–45. doi: 10.1007/s40263-017-0486-0.

Reese HE, Scahill L, Peterson AL, Crowe K, Woods DW, Piacentini J, et al. The premonitory urge to tic: measurement, characteristics, and correlates in older adolescents and adults. *Behav Ther*. 2014;45:177–86. doi: 10.1016/j.beth.2013.09.002.

Regeur L, Pakkenberg B, Fog R, Pakkenberg H. Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome. *J Neurol Neurosurg Psychiatry*. 1986;49:791–5. doi: 10.1136/jnnp.49.7.791.

Ribot B, Aupy J, Vidailhet M, Mazère J, Pisani A, Bezard E, et al. Dystonia and dopamine: From phenomenology to pathophysiology. *Prog Neurobiol*. 2019;182:101678. doi: 10.1016/j.pneurobio.2019.101678.

Ricciardi L, Pringsheim T, Barnes TRE, Martino D, Gardner D, Remington G, et al. Treatment Recommendations for Tardive Dyskinesia. *Can J Psychiatry*. 2019;64:388–99. doi: 10.1177/0706743719828968.

Rickards H, Hartley N, Robertson MM. Seignot's paper on the treatment of Tourette's syndrome with haloperidol. *Classic Text No. 31. Hist Psychiatry*. 1997;8:433–6. doi: 10.1177/0957154X9700803109.

Rickards H, Robertson MM. Vomiting and retching in Gilles de la Tourette syndrome: a report of ten cases and a review of the literature. *Mov Disord*. 1997;12:531–5. doi: 10.1002/mds.870120409.

Ricketts EJ, Rozenman M, Choy C, Goldberg HB, Kim JS, Colwell CS, et al. Sleep Sufficiency in Pediatric and Adolescent Tourette's Disorder: National Survey of Children's Health. *J Dev Behav Pediatr*. 2018;39:72–6. doi: 10.1097/DBP.0000000000000518.

Rizzo R, Gulisano M, Martino D, Robertson MM. Gilles de la Tourette Syndrome, Depression, Depressive Illness, and Correlates in a Child and Adolescent Population. *J Child Adolesc Psychopharmacol*. 2017;27:243–9. doi: 10.1089/cap.2016.0120.

Rizzo R, Gulisano M, Pavone P, Fogliani F, Robertson MM. Increased antistreptococcal antibody titers and anti-basal ganglia antibodies in patients with Tourette syndrome: controlled cross-sectional study. *J Child Neurol*. 2006;21:747–53. doi: 10.1177/08830738060210091001.

Robakis D. How Much Do We Know about Adult-onset Primary Tics? Prevalence, Epidemiology, and Clinical Features. *Tremor Other Hyperkinet Mov (N Y)*. 2017;7:441. doi: 10.7916/D8SQ95ND.

Robbins TW, Costa RM. Habits. *Curr Biol*. 2017;27:R1200–6. doi: 10.1016/j.cub.2017.09.060.

Robertson MM. Tourette syndrome, associated conditions and the complexities of treatment. *Brain*. 2000;123:425–62. doi: 10.1093/brain/123.3.425.

Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: the epidemiological and prevalence studies. *J Psychosom Res*. 2008a;65:461–72. doi: 10.1016/j.jpsychores.2008.03.006.

Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 2: tentative explanations for differing prevalence figures in GTS, including the possible effects of psychopathology, aetiology, cultural differences, and differing phenotypes. *J Psychosom Res*. 2008b;65:473–86. doi: 10.1016/j.jpsychores.2008.03.007.

Robertson MM. A personal 35 year perspective on Gilles de la Tourette syndrome: prevalence, phenomenology, comorbidities, and coexistent psychopathologies. *Lancet Psychiatry*. 2015;2:68–87. doi: 10.1016/S2215-0366(14)00132-1.

Robertson MM, Eapen V, Singer HS, Martino D, Scharf JM, Paschou P, et al. Gilles de la Tourette syndrome. *Nat Rev Dis Primers*. 2017;3:16097. doi: 10.1038/nrdp.2016.97.

Roessner V, Hoekstra PJ, Rothenberger A. Tourette's disorder and other tic disorders in DSM-5: a comment. *Eur Child Adolesc Psychiatry*. 2011a;20:71–4. doi: 10.1007/s00787-010-0143-3.

Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. *Eur Child Adolesc Psychiatry*. 2011b;20:173–96. doi: 10.1007/s00787-011-0163-7.

Rogers HL, Bhattaram A, Zineh I, Gobburu J, Mathis M, Laughren TP, et al. CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations. *J Clin Psychiatry*. 2012;73:1187–90. doi: 10.4088/JCP.11m07572.

Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. *Am J Psychiatry*. 1978;135:585–7. doi: 10.1176/ajp.135.5.585.

Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. *Mol Psychiatry*. 2010;15:53–63. doi: 10.1038/mp.2008.94.

Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. *J Am Acad Child Adolesc Psychiatry*. 2000;39:292–9. doi: 10.1097/00004583-200003000-00010.

Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. *Am J Psychiatry*. 1997;154:1057–62. doi: 10.1176/ajp.154.8.1057.

Sandor P, Musisi S, Moldofsky H, Lang A. Tourette syndrome: a follow-up study. *J Clin Psychopharmacol*. 1990;10:197–9.

Sandor P, Stephens RJ. Risperidone treatment of aggressive behavior in children with Tourette syndrome. *J Clin Psychopharmacol*. 2000;20:710–2. doi: 10.1097/00004714-200012000-00025.

Sanger TD, Chen D, Fehlings DL, Hallett M, Lang AE, Mink JW, et al. Definition and classification of hyperkinetic movements in childhood. *Mov Disord*. 2010;25:1538–49. doi: 10.1002/mds.23088.

Scahill L, Chappell PB, Kim YS, Schultz RT, Katsoyich L, Shepherd E, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. *Am J Psychiatry*. 2001;158:1067–74. doi: 10.1176/appi.ajp.158.7.1067.

Scahill L, Leckman JF, Schultz RT, Katsoyich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. *Neurology*. 2003;60:1130–5. doi: 10.1212/01.wnl.0000055434.39968.67.

Scharf JM, Yu D, Mathews CA, Neale BM, Stewart SE, Fagerness JA, et al. Genome-wide association study of Tourette's syndrome. *Mol Psychiatry*. 2013;18:721–8. doi: 10.1038/mp.2012.69.

Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. *Arch Gen Psychiatry*. 1982;39:486–7. doi: 10.1001/archpsyc.1982.04290040080014.

Schrag A, Martino D, Apter A, Ball J, Bartolini E, Benaroya-Milshtein N, et al. European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. *Eur Child Adolesc Psychiatry*. 2019;28:91–109. doi: 10.1007/s00787-018-1190-4.

Schrock LE, Mink JW, Woods DW, Porta M, Servello D, Visser-Vandewalle V, et al. Tourette Syndrome Association International Deep Brain Stimulation (DBS) Database and Registry Study Group. Tourette syndrome deep brain stimulation: a review and updated recommendations. *Mov Disord*. 2015;30:448–71. doi: 10.1002/mds.26094.

Schuerholz LJ, Baumgardner TL, Singer HS, Reiss AL, Denckla MB. Neuropsychological status of children with Tourette's syndrome with and without attention deficit hyperactivity disorder. *Neurology*. 1996;46:958–65. doi: 10.1212/wnl.46.4.958.

Shapiro AK, Shapiro E. Treatment of Gilles de la Tourette's Syndrome with haloperidol. *Br J Psychiatry*. 1968;114:345–50. doi: 10.1192/bjp.114.508.345.

Shapiro AK, Shapiro E. Controlled study of pimozide vs. placebo in Tourette's syndrome. *J Am Acad Child Psychiatry*. 1984;23:161–73. doi: 10.1097/00004583-198403000-00007.

Shapiro AK, Shapiro E, Eisenkraft GJ. Treatment of Gilles de la Tourette syndrome with pimozide. *Am J Psychiatry*. 1983;140:1183–6. doi: 10.1176/ajp.140.9.1183.

Shapiro AK, Shapiro E, Wayne H. Treatment of Tourette's syndrome with haloperidol, review of 34 cases. *Arch Gen Psychiatry*. 1973;28:92–7. doi: 10.1001/archpsyc.1973.01750310070010.

Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Arripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. *Neuropsychopharmacology*. 2003;28:1400–11. doi: 10.1038/sj.npp.1300203.

Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordlie J, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. *Arch Gen Psychiatry*. 1989;46:722–30. doi: 10.1001/archpsyc.1989.01810080052006.

Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). *Ann Pharmacother*. 2014;48:209–25. doi: 10.1177/1060028013510699.

Shimasaki C, Frye RE, Trifiletti R, Cooperstock M, Kaplan G, Melamed I, et al. Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes in patient symptoms. *J Neuroimmunol*. 2020;339:577138. doi: 10.1016/j.jneuroim.2019.577138.

Silvestri PR, Baglioni V, Cardona F, Cavanna AE. Self-concept and self-esteem in patients with chronic tic disorders: A systematic literature review. *Eur J Paediatr Neurol*. 2018;22:749–56. doi: 10.1016/j.ejpn.2018.05.008.

Singer C, Sanchez-Ramos J, Weiner WJ. A case of post-traumatic tic disorder. *Mov Disord*. 1989;4:342–4. doi: 10.1002/mds.870040409.

Singer H, Mink J, Gilbert D, Jankovic J. Tics and Tourette Syndrome. In: *Movement Disorders in Childhood*. London: Elsevier; 2016. p 40-55.

Singer HS. Tourette's syndrome: from behaviour to biology. *Lancet Neurol*. 2005;4:149–59. doi: 10.1016/S1474-4422(05)01012-4.

Singer HS. Autoantibody-Associated Movement Disorders in Children: Proven and Proposed. *Semin Pediatr Neurol*. 2017;24:168–79. doi: 10.1016/j.spen.2017.08.003.

Singer HS. Tics and Tourette Syndrome. *Continuum (Minneapolis)*. 2019;25:936–58. doi: 10.1212/CON.0000000000000752.

Singer HS, Butler IJ, Tune LE, Seifert WE Jr, Coyle JT. Dopaminergic dysfunction in Tourette syndrome. *Ann Neurol*. 1982;12:361–6. doi: 10.1002/ana.410120408.

Singer HS, Gilbert DL, Wolf DS, Mink JW, Kurlan R. Moving from PANDAS to CANS. *J Pediatr*. 2012;160:725–31. doi: 10.1016/j.jpeds.2011.11.040.

Singer HS, Giuliano JD, Hansen BH, Hallett JJ, Laurino JP, Benson M, et al. Antibodies against human putamen in children with Tourette syndrome. *Neurology*. 1998;50:1618–24. doi: 10.1212/wnl.50.6.1618.

Singer HS, Giuliano JD, Zimmerman AM, Walkup JT. Infection: a stimulus for tic disorders. *Pediatr Neurol*. 2000;22:380–3. doi: 10.1016/s0887-8994(00)00131-4.

Singer HS, Hong JJ, Yoon DY, Williams PN. Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls. *Neurology*. 2005;65:1701–7. doi: 10.1212/01.wnl.0000183223.69946.fl.

Singer HS, Schuerholz LJ, Denckla MB. Learning difficulties in children with Tourette syndrome. *J Child Neurol*. 1995;10 Suppl 1:58-61. doi: 10.1177/08830738950100S112.

Singer HS, Wendlandt J, Krieger M, Giuliano J. Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. *Neurology*. 2001;56:599–604. doi: 10.1212/wnl.56.5.599.

Smith-Hicks CL, Bridges DD, Paynter NP, Singer HS. A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. *Mov Disord*. 2007;22:1764–70. doi: 10.1002/mds.21615.

Snider LA, Seligman LD, Ketchen BR, Levitt SJ, Bates LR, Garvey MA, et al. Tics and problem behaviors in schoolchildren: prevalence, characterization, and associations. *Pediatrics*. 2002;110:331–6. doi: 10.1542/peds.110.2.331.

Specht MW, Mahone EM, Kline T, Waranch R, Brabson L, Thompson CB, et al. Efficacy of parent-delivered behavioral therapy for primary complex motor stereotypies. *Dev Med Child Neurol*. 2017;59:168–73. doi: 10.1111/dmcn.13164.

Specht MW, Nicotra CM, Kelly LM, Woods DW, Ricketts EJ, Perry-Parrish C, et al. A Comparison of Urge Intensity and the Probability of Tic Completion During Tic Freely and Tic Suppression Conditions. *Behav Modif.* 2014;38:297–318. doi: 10.1177/0145445514537059.

Spencer T, Biederman M, Coffey B, Geller D, Wilens T, Faraone S. The 4-year course of tic disorders in boys with attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry.* 1999;56:842–7. doi: 10.1001/archpsyc.56.9.842.

Spencer T, Biederman J, Harding M, O'Donnell D, Wilens T, Faraone S, et al. Disentangling the overlap between Tourette's disorder and ADHD. *J Child Psychol Psychiatry.* 1998;39:1037–44. doi.wiley.com/10.1111/1469-7610.00406.

Stefanoff P, Wolanczyk T, Gawrys A, Swirszcz K, Stefanoff E, Kaminska A, et al. Prevalence of tic disorders among schoolchildren in Warsaw, Poland. *Eur Child Adolesc Psychiatry.* 2008;17:171–8. doi: 10.1007/s00787-007-0651-y.

Stephens RJ, Bassel C, Sandor P. Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome - A pilot study. *J Child Adolesc Psychopharmacol.* 2004;14:255–66. doi: 10.1089/1044546041648959.

Stewart SE, Illmann C, Geller DA, Leckman JF, King R, Pauls DL. A controlled family study of attention-deficit/hyperactivity disorder and Tourette's disorder. *J Am Acad Child Adolesc Psychiatry.* 2006;45:1354–62. doi: 10.1097/01.chi.0000251211.36868.fe.

Stiede JT, Alexander JR, Wellen B, Bauer CC, Himle MB, Mouton-Odum S, et al. Differentiating tic-related from non-tic-related impairment in children with persistent tic disorders. *Compr Psychiatry.* 2018;87:38–45. doi: 10.1016/j.comppsy.2018.07.017.

Stoner SC. Management of serious cardiac adverse effects of antipsychotic medications. *Ment Health Clin.* 2018;7:246–54. doi: 10.9740/mhc.2017.11.246.

Storch EA, Hanks CE, Mink JW, McGuire JF, Adams HR, Augustine EF, et al. SUICIDAL THOUGHTS AND BEHAVIORS IN CHILDREN AND ADOLESCENTS WITH CHRONIC TIC DISORDERS. *Depress Anxiety.* 2015;32:744–53. doi: 10.1002/da.22357.

Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. *World Psychiatry.* 2018;17:341–56. doi: 10.1002/wps.20567.

Sukhodolsky DG, Scahill L, Zhang H, Peterson BS, King RA, Lombroso PJ, et al. Disruptive behavior in children with Tourette's syndrome: association with ADHD comorbidity, tic severity, and functional impairment. *J Am Acad Child Adolesc Psychiatry.* 2003;42:98–105. doi: 10.1097/00004583-200301000-00016.

Sundaram SK, Huq AM, Wilson BJ, Chugani HT. Tourette syndrome is associated with recurrent exonic copy number variants. *Neurology.* 2010;74:1583–90. doi: 10.1212/WNL.0b013e3181e0f147.

Swedo SE, Leonard HL, Rapoport JL. The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) subgroup: separating fact from fiction. *Pediatrics.* 2004;113:907–11. doi: 10.1542/peds.113.4.907.

Termine C, Luoni C, Fontolan S, Selvini C, Perego L, Pavone F, et al. Impact of co-morbid attention-deficit and hyperactivity disorder on cognitive function in male children with Tourette syndrome: A controlled study. *Psychiatry Res.* 2016;243:263–7. doi: 10.1016/j.psychres.2016.06.048.

Thienemann M, Murphy T, Leckman J, Shaw R, Williams K, Kappahn C, et al. Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part I-Psychiatric and Behavioral Interventions. *J Child Adolesc Psychopharmacol.* 2017;27:566–73. doi: 10.1089/cap.2016.0145.

Tourette's Syndrome Study Group. Short-term versus longer term pimozide therapy in Tourette's syndrome: a preliminary study. *Neurology.* 1999;52:874–7. doi: 10.1212/wnl.52.4.874.

Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. *Neurology.* 2002;58:527–36. doi: 10.1212/wnl.58.4.527.

Ueda K, Kim S, Greene DJ, Black KJ. Correlates and clinical implications of tic suppressibility. 2020. OSF Preprints: <https://osf.io/5sg2d/>

Verdellen CW, Keijsers GP, Cath DC, Hoogduin CA. Exposure with response prevention versus habit reversal in Tourette's syndrome: a controlled study. *Behav Res Ther.* 2004;42:501–11. doi: 10.1016/S0005-7967(03)00154-2.

Verkerk AJ, Mathews CA, Joosse M, Eussen BH, Heutink P, Oostra BA; Tourette Syndrome Association International Consortium for Genetics. CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and obsessive compulsive disorder. *Genomics.* 2003;82:1–9. doi: 10.1016/s0888-7543(03)00097-1.

Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J. Deep brain stimulation for Tourette syndrome: target selection. *Stereotact Funct Neurosurg.* 2012;90:213–24. doi: 10.1159/000337776.

Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. *Tremor Other Hyperkinet Mov (N Y).* 2013;3:tre-03-161-4138-1. doi: 10.7916/D88P5Z71.

Wang S, Mandell JD, Kumar Y, Sun N, Morris MT, Arbelaez J, et al. De Novo Sequence and Copy Number Variants Are Strongly Associated with Tourette Disorder and Implicate Cell Polarity in Pathogenesis. *Cell Rep.* 2018;25:3544. doi: 10.1016/j.celrep.2018.12.024.

Weidinger E, Krause D, Wildenauer A, Meyer S, Gruber R, Schwarz MJ, et al. Impaired activation of the innate immune response to bacterial challenge in Tourette syndrome. *World J Biol Psychiatry.* 2014;15:453–8. doi: 10.3109/15622975.2014.907503.

Wenzel C, Wurster U, Müller-Vahl KR. Oligoclonal bands in cerebrospinal fluid in patients with Tourette's syndrome. *Mov Disord.* 2011;26:343–6. doi: 10.1002/mds.23403.

Widschwendter CG, Hofer A. Antipsychotic-induced tardive dyskinesia: update on epidemiology and management. *Curr Opin Psychiatry.* 2019;32:179–84. doi: 10.1097/YCO.0000000000000491.

Wilhelm S, Peterson AL, Piacentini J, Woods DW, Deckersbach T, Sukhodolsky DG, et al. Randomized trial of behavior therapy for adults with Tourette syndrome. *Arch Gen Psychiatry*. 2012;69:795–803. doi: 10.1001/archgenpsychiatry.2011.1528.

Williams KA, Swedo SE, Farmer CA, Grantz H, Grant PJ, D'Souza P, et al. Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Auto-immune Neuropsychiatric Disorders Associated With Streptococcal Infections. *J Am Acad Child Adolesc Psychiatry*. 2016;55:860–7. doi: 10.1016/j.jaac.2016.06.017.

Woods DW, Piacentini J, Himle MB, Chang S. Premonitory Urge for Tics Scale (PUTS): initial psychometric results and examination of the premonitory urge phenomenon in youths with Tic disorders. *J Dev Behav Pediatr*. 2005;26:397–403. doi: 10.1097/00004703-200512000-00001.

Worbe Y, Mallet L, Golmard JL, Béhar C, Durif F, Jalenques I, et al. Repetitive behaviours in patients with Gilles de la Tourette syndrome: tics, compulsions, or both? *PLoS One*. 2010;5:e12959. doi: 10.1371/journal.pone.0012959.

Yael D, Vinner E, Bar-Gad I. Pathophysiology of tic disorders. *Mov Disord*. 2015;30:1171–8. doi: 10.1002/mds.26304.

Yanagisawa N, Goto A. Dystonia musculorum deformans. Analysis with electromyography. *J Neurol Sci*. 1971;13:39–65. doi: 10.1016/0022-510x(71)90206-1.

Yoo HK, Joong YS, Lee JS, Song DH, Lee YS, Kim JW, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. *J Clin Psychiatry*. 2013;74:e772–80. doi: 10.4088/JCP.12m08189.

Yu D, Mathews CA, Scharf JM, Neale BM, Davis LK, Gamazon ER, et al. Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. *Am J Psychiatry*. 2015;172:82–93. doi: 10.1176/appi.ajp.2014.13101306.

Yu J, Ye Y, Liu J, Wang Y, Peng W, Liu Z. Acupuncture for Tourette Syndrome: A Systematic Review. *Evid Based Complement Alternat Med*. 2016;2016:1834646. doi: 10.1155/2016/1834646.

Yung CY. Clinical features of movement disorders. *Brain Res Bull*. 1983;11:167–71. doi: 10.1016/0361-9230(83)90185-5.

Zhu P, Wu M, Huang P, Zhao X, Ji X. Children from nuclear families with bad parental relationship could develop tic symptoms. *Mol Genet Genomic Med*. 2020;8:e1286. doi: 10.1002/mgg3.1286.

Zutshi D, Cloud LJ, Factor SA. Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic. *Tremor Other Hyperkinet Mov (N Y)*. 2014;4:266. doi: 10.7916/D8MS3R8C.